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General aim of thesis
For this thesis, we have examined the effects of increasing doses of 
immunosuppressant drugs at relevant time points, in order to untangle the 
detrimental effect that many immunosuppressant drugs are believed to have on 
wound healing.
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Chapter 1
Immune suppressant therapy and its history
Immunosuppressant therapy is presently inevitable in solid organ transplantation, 
and most drugs in the poly-drug regimen of medication have been, justly or not, 
associated with wound healing complications. This thesis attends to the wound-
healing complications of immune suppressant therapy and starts with the history 
of development of immunosuppressant therapy and an overview of the possible 
contemporary immune suppressant drugs for solid organ transplantation.
Solid organ transplantation would not have been possible without the development 
of immunosuppressant drugs. In the first half of the 20th century, which was decades 
before the introduction of immunosuppressant therapy, attempts were made to 
transplant the kidney of an animal or deceased human donor into a recipient, usually 
with discouraging results. Although World War II prompted the medical profession 
to search for a way to effectively transplant skin from human to human and boosted 
the research for transplantation, only identical twin kidney transplantation was 
more or less successful until the early 1960’s. Rene Kuss, a French surgeon who in 
1951 introduced the extraperitoneal approach for kidney transplantation that is still 
used today, stated in his famous publication in Mem Acad Chir (1951) that “in the 
present state of knowledge, the only rational basis for kidney replacement would be 
between monozygotic twins”.1 Apparently, at this point, the concept of an immune 
related rejection was well established. 
In the fifties and early sixties sub lethal total body irradiation was tried in order 
to avoid rejection but abandoned because of repeated failures.2 In 1960 Willard 
Goodwin started to add corticosteroids to the therapy and Roy Calne started to 
test 6 mercaptopurine in dog transplants.3,4 In 1959 the first successful non-twin 
sibling living transplant was carried out in Paris and in 1960 in the United Kingdom. 
The recipient in the UK received prednisolone and 6 mercaptopurine.5 Success was 
defined completely different in those early days compared to our standards: the 
recipient in the UK lived 7 weeks. In 1962 azathioprine (related to 6 mercaptopurine) 
was introduced and led to the first long term successful transplantation of a 
deceased donor kidney.6 This recipient lived one year. In 1963 Thomas Starzyl 
combined prednisolone and azathioprine and introduced an effective way of dual 
immunosuppressant therapy.7 In september 1963 a meeting was organized in 
Washington where teams from France, the United Kingdom and the USA met. Prior 
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to the conference all participants were sent blank data sheets which they returned 
before the conference. This made an analysis possible of practically every human 
kidney transplant up to the first of July in 1963. The results were poor: 52% of the 
patients receiving a kidney from a live, related, donor had died, as well as 81% of 
the recipients of unrelated live donor kidneys or deceased donor kidneys.8 However, 
the teams carried on with the research and progress was made fast, showing a one 
year survival rate of 80% for live donor recipients in 1965 and 65% for deceased 
donor recipients.9 
With the use of immune suppressant therapy one needs to find the balance between 
the prevention of rejection and the health of the patient that needs to be protected 
against severe side effects such as opportunistic infections, malignancies and 
cardiovascular diseases. In earlier days rejection rates were high and graft loss due 
to rejection was frequent. The main goal in those days was to prevent rejection and 
improve short term patient and graft survival. Side effects did not have much of a 
priority. Now that we have become much more successful in preventing rejection by 
immunosuppressant therapy and better histocompatibility matching of donor and 
recipient, the attention has shifted towards diminishing toxic side effects, long term 
recipient survival and improving quality of live. Kidney transplantation is carried out 
at older age and recipients reach a more advanced age, making them prone for future 
diseases and future operations. Common maintenance immunosuppressive therapy 
nowadays consists of an initial triple or quadriple regimen of a calcineurin inhibitor 
(cyclosporine or tacrolimus), mycophenolate mofetil and steroids with or without 
the use of induction therapy. Various alternative combinations are applied for special 
circumstances, such as drug intolerance. We will discuss the immunosuppressant 
medication tested in this thesis.
mTOR inhibitors:
Sirolimus was originally discovered during a search for new anti-microbial agents. In a 
soil sample at Rapa Nui (or Easter Island), a strain of streptomyces hygroscopicus was 
found which produced a strong macrolide antibiotic with anti-fungal properties.10 
The drug was marketed under the trade name Rapamune, but is better known as 
sirolimus. Structurally similar to the calcineurine inhibitor tacrolimus, it proved to 
have potent immunosuppressive properties with a novel method of action which was 
first described by Sehgal.11 Sirolimus binds to the same intracellular binding protein 
as tacrolimus, but instead of inhibiting calcineurin, the complex blocks the function 
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of the mammalian target of rapamycin (mTOR).11,12 The inhibited mTOR-mediated 
pathways result in the arrest of cell cycle in the G1 phase in various cell types, 
including T-and B-lymfocytes, and thus constitutes a potent immunosuppressive 
tool. Everolimus, a newer mTOR inhibitor and derivate of rapamycine, is very similar 
to sirolimus in pharmacodynamic effects.12
Although rapamycine was already discovered in the seventies, interest in its use in 
transplantation surgery started a few decades later. Initially, the trials focused on 
the use of sirolimus as adjunct to cyclosporine and prednisone, often substituting 
for azathioprine.10 In 2000 sirolimus was registered in Europe and the United 
States as an alternative for maintenance therapy after the discontinuitation of 
cyclosporine at three months post transplantation in recipients who were at low 
risk for rejection.10 The aim of research became to use mTOR inhibitors and minimize 
cyclosporine and steroid exposure, because of the relatively strong side effects of 
these drugs. Addition of an mTOR inhibitor to the polydrug post transplantation 
regimen seemed promising at first, but when sufficient clinical experience had been 
gathered, specific adverse effects came to light. An important clinical side effect 
that has been recognized is a negative influence of mTOR inhibitors on wound repair. 
Wound healing disorders were seen in 7–53% of renal transplantation patients and 
rapamycin derivatives (e.g. sirolimus) seemed to play an important role.13-20 The same 
phenomenon was noted in cardiac transplant recipients.21-24 
Tacrolimus: 
In contrast to most immunosuppressive drugs, tacrolimus, a macrolide derived from 
the fungus S tsukubaensis in a Japanese soil sample in 1987, is believed to have few 
or no adverse effects on wound healing. In the early literature also known as FK-
506, tacrolimus is a macrolide calcineurin inhibitor. Calcineurin dephosphorylates 
the transcription factor Nuclear Factor of activated T-cells (NF-AT), which moves to 
the nucleus of the T-cell and increases the activity of genes coding for IL-2 and 
related cytokines. Tacrolimus prevents the dephosphorlysation of NF-AT. Although 
cyclosporine and tacrolimus essentially inhibit the action of calcineurin in the 
same way, their side effects differ slightly. Tacrolimus is superior to cyclosporine 
in preventing acute rejection and improving graft survival which has resulted in an 
enormous increase in use of the agent since introduction in 1989.25 Tacrolimus has 
a greater effect on impairing the expression of alloantigen stimulated T-lymfocytes 
than does cyclosporine but supposedly a less significant effect on wound healing.26 
13
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Extensive research has been carried out to establish the benefit of tacrolimus over 
cyclosporine.15,25,27 Still, as a calcineurin inhibitor, tacrolimus affects the first phase 
of T-cell activation. Because inflammatory T cells play a role in wound healing an 
effect of tacrolimus on wound healing is conceivable. Reported effects of tacrolimus 
in preclinical studies have been contradictory, ranging from stimulation to inhibition 
of soft tissue repair.28-32
Mycophenolate mofetil (MMF) 
Mycophenolic acid is a fungal metabolite that was initially discovered by Bartolomeo 
Gosio in 1893 as an antibiotic against anthrax bacillus. It has also been reported to 
possess antiviral, antifungal, anti-tumor and anti-psoriasis activities.33 It has been 
used as an immunosuppressant in kidney, heart and liver transplantation since the 
nineties. Mycophenolate mofetil (MMF) is the morpholinoethylester of mycophenolic 
acid. MMF is the “prodrug” which is metabolized in the active mycofenolic acid (MPA), 
a specific inhibitor of inosine monofosphate dehydrogenase. This is a key enzyme for 
de novo synthesis of guanosine nucleotides, essential for DNA and RNA synthesis 
and necessary for maximum lymphocyte proliferation. The immune suppressant 
action is therefore based on a decrease of proliferation of T and B lymphocytes and 
monocytes. By depleting the intracellular concentration of guanosine nucleotides, 
MPA acts as a potent inhibitor of lymphocyte proliferation. There is also evidence 
that MMF inhibits the action of fibroblasts and other cells that are not part of the 
immune system.34 A negative effect of MMF on wound healing is therefore plausible, 
even when started postoperatively, as is the case in new transplant recipients. 
In oncology and transplantation surgery immunosuppressant drugs have a bad image 
when it comes to wound healing. Without much evidence surgeons all over the world 
are afraid of wound healing disturbances when patients use agents that suppress 
their immune system. This can be based on true scientific observations, but is often 
based on a gut feeling. Contradictory evidence can be found in the literature for many 
agents. The problem with most clinical studies is that wound healing is not a primary 
endpoint but part of a standard adverse event listing, that might be vulnerable 
to reporting bias. Compared to the vast amount of studies concerning transplant 
survival few studies or reviews have focused on wound healing. Furthermore: in 
clinical studies, all of the mentioned drugs are invariably used together. This makes 
it almost impossible to entangle the effect of the individual drug on wound healing. 
1
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Safety in terms of interference with wound repair must therefore also be assessed 
in a preclinical model.
Kidney transplant recipients: Changes in demographics and who are we treating?
The demographics of kidney transplant recipients are changing over time and have 
been changing since the start of solid organ transplantation. First of all, due to a 
steady rise in numbers of solid organ transplantation, as well as a marked increase 
in efficacy and safety of the immunosuppressant treatment scheme, the number 
of patients alive with a functioning kidney transplant is ever increasing.35 This 
cannot primarily be attributed to a decrease in mortality. Although mortality of 
renal transplant recipients has decreased dramatically in earlier decades, mortality 
(death with functioning graft) has changed little since 1991. For deceased donor 
kidney recipients in the United States of America, death with functioning graft 
at 5 years post transplantation has remained more or less the same since 1991, 
and has increased at 10 years, probably due to older patients receiving a kidney 
transplant.36 For living donor recipients, death with functioning graft at 5 year post 
transplantation has decreased since the year 2000. However, the 10 year rate has 
been generally increasing since that time.36
It appears that the marked increase in long term survival of the patient of earlier 
decades has now come to a halt. However, the probability of returning to dialysis or 
repeat transplantation is decreasing. Data of the United States Renal Data System 
(USRDS) show us that this probability decreases significantly, as does the all cause 
graft failure.35 In recipients of deceased donor kidneys the 5 year probability of 
returning to dialysis or repeat transplantation was 25,7% in 1996 and 16,2% in 2008. 
At 10 years these percentages were respectively 42,9% in 1996 and 36,1% in 2003.35 
For living donor kidney recipients these figures are lower, as can be expected, but 
also decreasing in the last decade. The 5 year probability of recipients of living donor 
kidneys of returning to dialysis or repeat transplantation is 16,8% in 1996 and 9,9% 
in 2008. At 10 years these percentages are respectively 32,4% in 1996 and 26,1% 
in 2003.35 The USRDS annual report states that even though the number of kidney 
transplants has remained stable since 2005, the cumulative number of recipients 
living with a functioning kidney continues to grow. From 2012 to 2013 again a 3.1% 
increase in the cumulative number of recipients with functioning kidney transplant 
was noted in the United States of America.35 
15
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Demographics on survival of kidney transplant recipients like the USRDS are more 
difficult to assess for European patients where a registry covering all countries 
does not exist. In Europe multiple national and international foundations exist. 
These foundations often have alliances with each other. In 1982 an initiative called 
the Collaborative Transplant Study (CTS) was started in Heidelberg, in which over 
400 individual transplant centers throughout the world joined voluntarily. The 
purpose of this initiative is scientific. In 2013 a comparison of data from the CTS 
in Europe and data from the United Network for Organ Sharing (UNOS)/Organ 
Procurement and Transplantation of the United States of America was carried out.37 
In this study by Gondos et al, both patient and death-censored graft survival in the 
years 2005 to 2008 were the same for the European population and the United 
States of America population at one year after transplantation. However, at 2-5 
years after transplantation graft survival was found to be significantly different 
for all age groups and populations. At ten years, graft survival for recipients of a 
first transplantation with a deceased donor kidney was highest in Europe (56.5%). 
Estimates for the three US populations where respectively 45.7%, 33.7% and 48.2% 
for white American, African American and Hispanic American recipients. All the 
differences where highly significant. 37 It seems therefore likely that the amount of 
patients living with a functioning graft will rise in Europe even more than in the 
United States of America.
Another reason for the increase in living recipients of a functioning kidney transplant 
is the rise in numbers of living donor kidney transplantation in the last four decades. 
URDS statistics have shown an increase in numbers of living donor kidney transplants 
until 2004 and a stabilization thereafter.35 However, although graft survival half 
life is higher for living donor kidney recipients, the graft survival has not further 
improved for this group, as it did for the deceased donor transplantations between 
1989 and 2005.41 Not only numbers, but also survival of the living donor kidney 
transplantation seem to plateau in the last decade in the United States of America.
Demographics for European patients are, as explained before, collected by multiple 
national and international foundations. The Eurotransplant International Foundation, 
commonly known as Eurotransplant, is the international non-profit organization 
organizing transplantation allocations for Austria, Belgium, Croatia, Germany, 
Hungary, Luxembourg, Netherlands, and Slovenia. Scandiatransplant is the organ 
exchange organization for the Nordic countries Denmark, Finland, Iceland, Norway 
1
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and Sweden. The council of Europe Newsletter Transplant, published by EDQMC 
Council of Europe, provides international figures on organ, tissue and haemopoetic 
stem cell donation and transplantation. This work is carried out under the aegis 
of the European Committee on Organ Transplantation (CD-P-TO) and co-ordinated 
by the Spanish National Transplant Organisation (ONT). 42 The percentage live 
kidney transplantation from total kidney transplantation in these countries varies 
from 0 to approximately 60%. Variability among countries is high. In contrast to 
the numbers from the USRDS the total amount of kidney transplantations in the 
European registries is still rising. From 2006 until 2014 the total amount of kidney 
transplantations in the Eurotransplant countries, UK and Scadiatransplant countries 
increased with 22% to slightly more than 9000 kidney transplantations in 2014.43-48 
(Figure 1,2)
Figure 1 Numbers of total kidney transplantations per million inhabitants, the percentage kidney trans-
plantation with live donor kidneys of the total number of kidney transplantations and the number of 
kidney transplantations with live donors per million inhabitants in 18 European countries, in 2014. 42
17
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Figure 2 Cumulative numbers of Eurotranplant, UK registry and Scandiatransplant of living donor kidney 
transplantations, deceased donor kidney transplantations and the total numbers.43-48
 
In conclusion, due to different reasons such as a longer graft survival , a rise in live 
kidney donation and, in Europe, and a rise in total numbers of kidney transplantation, 
more individuals are living with a functioning kidney graft. 
Other demographic changes
Apart from the increase in numbers, patients receiving a kidney transplant are also 
becoming older and more overweight. In the Eurotransplant Annual Reports the 
percentage of patients aged over 65 has been rising from 23.8% in 2006 to 26.3% 
in 2014.43,44 In the United Kingdom the median age of the kidney recipient is slowly 
rising from 45.2 years in 2006 to 50.6 in 2014.45-48 A growing number of patients, 
rising in age, is therefore dependent on immunosuppressant drugs for transplant 
survival. This is important not only during the transplantation itself but also later in 
life, when patients are prone to be in need of other forms of surgery. The proportion 
of deaths attributed to malignancy in the first decade after transplantation is as 
high as 26 % and rising.49 Presumably, this phenomenon will result in a rise in 
future operations not related to the transplanted organ. Surgeons therefore, are 
increasingly confronted with transplanted patients in need of an operation, either 
1
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related to their transplanted organ or to other diseases.50-53 Surgery needs to be 
executed under immunosuppressant therapy, possibly with increased chances of 
wound complications such as bowel leakage or incisional hernia. 
Mirroring the increasing incidence of obesity in the general population there has 
been an increase in obese recipients of a kidney transplant. Kramer et all showed 
an increase of obesity (Body Mass Index, BMI above 30) of 45% in end stage renal 
kidney disease patients between 1995 and 2001 using the United States Renal 
Data Systems (USRDS).54 Friedman et all investigated the United Network for Organ 
Sharing (UNOS) to determine the increase in obesity in kidney transplant recipients.55 
Of the recipients of a kidney transplant between 1987 and 2001 the proportion of 
overweight patients (BMI 25-29,5) rose with 32% while the proportion of obese 
recipients (BMI above 30) rose with 116%. Obesity in kidney transplant recipient is 
reason for much debate, where contradictory findings in complications are reported. 
In 2015 la Franca et all published a meta analysis including data of more than 
200.000 kidney transplant recipients dividing them in a group with BMI below 30 
and the other group with BMI above 30.56 Except for patient survival expressed 
in hazard ratio’s which was favourable for high BMI patients many other outcome 
measurements were in favour of low BMI. Especially wound infections and incisional 
hernias showed high relative risk in the high BMI patient group of respectively 2.72 
and 4.85. Lymphoceles and hematomas did not show any significant difference. 
In conclusion: the fact that more and more kidney transplant recipients are alive 
with functioning kidney transplant grafts, using the inevitable immunosuppressant 
therapy and getting older and more overweight, makes a big plea for an 
immunosuppressant therapy that is as safe as possible. In this thesis we have 
focussed on wound healing complications in case of use of immunosuppressant 
therapy. This can be either the initial transplantation or an operation later in life 
while still on immunosuppressant therapy.
Wound healing.
Wound healing is a very complex process. In the normal organ response of 
mammalian tissue to injury various intracellular and intercellular pathways are 
activated and must be coordinated. If the organism is not killed by the injury all 
initiated processes need to be shut down in a precise sequence. A wound is defined 
as a interruption of tissue of skin, mucosa or organ-tissue by any kind of trauma. 
19
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The process of wound healing is not dependent of the cause of the wound: wounds 
caused by mechanical, thermal or chemical trauma follow the same steps in wound 
healing.
Mammals have retained much of the capacity of wound healing but their 
regenerative potential is limited which seems to be the result of rapid interposition 
of fibrotic tissue, which closes the wound quickly but at the same time prevents 
subsequent tissue regeneration. The human heals by making fibrosis, in contrast to 
the human fetus that heals by regeneration. Healing by fibrosis can be looked upon 
as dysfunctional healing and often is responsible for lifelong disability, as is well 
demonstrated in the healing of myocardial infarction. Healing by regeneration, as 
not only the human fetus can, but also for example amphibians, is the area of much 
interest.57 Normal wound healing is traditionally characterized by several sequential, 
but also overlapping phases that are referred to as the inflammation, proliferation 
and remodeling phase.58,59 
Inflammatory phase from day 0 until day 4 to 6:
The initiating step of the wound healing process is hemostasis. This starts at the 
time the wound occurs with vasoconstriction of the injured blood vessels, adherence 
of platelets and cessation of bleeding. The platelets in the clot disintegrate and 
the α-granula of the thrombocytes release cytokines, growfactors and matrix 
proteins. Grow factors such as PDGF (platelet derived growth factor), IGF (insulin 
like growth factor), EGF (epidermal growth factor) and TGF-β (transforming growth 
factor β ) are especially important to maintain the progress of wound healing. They 
attract monocyts and neutrophils, that are able to leave the capillaries because of 
vasodilatation through local acidosis of the wound. The fibrin clot also functions 
as a scaffold for the invading cells. Neutrophils are the cells that dominate the 
wound in the first 24-48 hours. The most important task for the neutrophils is to 
destroy bacteria by excreting proteolytic enzymes and phagocytize the bacteria 
and the celldebris. Parallel to that they make cytokines that activate macrophages, 
keratinocytes and fibrinoblasts. Neutrophils succumb to an unknown stimulus for 
apoptosis after a short time.
Macrophages, evolved from monocytes, continue the work of the neutrophils. They 
are also able to introduce and direct the second phase of wound healing. In contrast 
to the neutrophils, monocytes are present in the wound until the end of the wound 
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healing. They are supported by T and B lymphocytes in the inflammatory and in 
the proliferative phase of wound healing. The damaged extracellular matrix is also 
cleared by matrix metalloproteinases (MMP’s), which are expressed by keratinocytes, 
fibroblast, monocytes and macrophages in repons to tumor necrosis factor α (TNFα). 
MMP clears inflammatory debris and enables migration of individual wound cells 
through the extracellular matrix.
Proliferative phase from day 4 until day 14:
About four days after the start of the wound, the inflammatory phase is ending and 
proliferative phase is started. The cellular debridement by phagocytosis has ended, 
acidosis and hypoxia are diminishing and granulation tissue is built. Fibroblasts, 
that were recruited from the edge of the wound in an early stage, proliferate and 
produce collagen. A second population of fibroblasts, the myofibroblast, come in and 
arrange the wound contraction. The extracellular matrix exists of proteoglycans, 
fibronectin and collagen. This matrix is getting stronger by a combined action of 
growth factors, proteases and protease-inhibitors.
In the granulation tissue typical capillaries are build by endothelium cells coming 
from the edge of the wound and from intact venules. This is made possible by the 
low oxygen tension and growth factors such as TNF-α, TGF-β, vascular endothelial 
growth factor (VEGF), fibroblast growth factor (FGF), PDGF and integrin. Fibroblast, 
fatcells, and muscle cells escort the endothelium cells and help build the granulation 
tissue. Angiogenesis starts as soon as 1-2 days after the start of the wound. The 
epithelialization of the wound is initiated at the edges of the wound were epithelial 
cells become active. They migrate in the direction of the middle of the wound. When 
they come in contact with epithelial cells from opposite side the migration stops 
and the epithelial mono-cell layer starts to become stronger in order to restore the 
function of barrier. 
Remodeling phase from day 8 until one year: 
The remodeling phase takes many months, analogue to the healing of bone. In this 
timeframe the collagen matrix is permanently restructured and the mechanical 
ability of the scar to withstand outside forces is increasing. 
21
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Introduction
Discovery of the relation between medication and wound healing disturbances:
Even before the administration of immunosuppressant drugs in transplantation, 
awareness about wound healing arose by the observation of Hench in 1949 that 
cortisone affected the inflammatory process of the joints of patients suffering from 
rheumatoid arthritis.1 This observation prompted different groups of researchers 
to start clinical and preclinical experiments for wound healing disturbances due 
to the use of cortisone or adrenal corticotrophic hormone (ACTH). Ragan et all 
reported three patients who formed poor granulation tissue while on ACTH2 and 
Creditor et all carried this observation further by biopsying the wounds and showing 
histological evidence of delayed formation of granulation tissue.3 However, in the 
early days of kidney transplantation, wound complications were the least important 
problem that physicians and patients had on their mind and for a long time wound 
complications in transplantation have drawn little interest. 
Impaired wound healing as a complication after transplantation
Wound complications are probably the most common surgical complication after 
transplantation.4 They usually do not lead to graft loss or death but can result in 
significant morbidity, prolonged hospitalization or re-admittance, and can lead to 
increased costs. Recipients of solid organ transplants are not only at risk for wound 
complications in the immediate post-transplantation period but also later in life 
when a need of surgery may arise while still on immunosuppressive drugs. Most 
clinical analysis of immunosuppressant drugs focus on transplant outcome and 
patient survival. Wound healing problems are not always recorded and are seldom 
the main reason for the study. The first reports in the literature addressing wound 
complications in kidney transplantation dates from the seventies. Schweizer et al 
observed and discussed the problem of septic wound complications in 1971.5 They 
demonstrated that wounds with large hematomas were particularly susceptible to 
septic complications. However, interest at that moment is focused on the use of 
topical antibiotic and on the incidence and treatment modalities of lymphoceles but 
not on the effect of immunosuppressant therapy on wound healing.6,7 
Reviews and metanalyses
In the literature of recent decades wound healing in organ transplant recipients 
was the main topic of very few papers. Searching the literature for studies that 
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were specifically carried out to evaluate wound healing in kidney transplantation, 
3 reviews, 1 systematic review and 1 study pooling data of 3 prospective studies 
were retrieved.8-13 They invariably include studies that are aimed to investigate 
graft or patient survival and provide data on complications as a by-product. One 
systematic review that is much cited by papers on wound healing is the review of 
Webster at all.14 This review does not focus on wound healing but the methodology 
used is very thorough, including non-English literature and unpublished data, 
and including the formation of lymphoceles when captured. They reviewed 33 
randomized trials. Their most striking finding was the high risk for developing 
lymphocele in the mTOR inhibitors group: they demonstrated a higher risk for 
lymphocele when they compared mTOR inhibitors with antimetabolites, such as 
MMF (four trials, RR 3.07;95%CI 1.87-5.06) and also when compared to calcineurine 
inhibitors (three trials, RR 3.06;95%CI 1.59-5.91).14 The excellent systematic review 
of Pengel et al from 2011, aimed at researching wound healing, included 28 studies 
in kidney transplantation up to march 2011.10 Pooled analysis showed a higher rate 
of wound complications and lymphoceles for kidney transplant recipients on mTOR 
inhibitors. Kidney transplant recipients receiving mTOR inhibitors together with 
antimetabolites also showed a higher rate of wound complications in the pooled 
analysis. A pooled analysis of two RCT’s showed less lymphoceles for early steroid 
withdrawal compared to late steroid withdrawal. The final conclusion of Pengel et 
al is that immediate use of mTOR inhibitors leads to a higher incidence of wound 
complications and lymphoceles. Not included in the review of Pengel is the paper 
of Lopau et al.15 This retrospective cohort study is one of the very few publications 
focusing on MMF and wound healing in clinical setting. In this study the amount of 
ultrasound controlled lymphoceles was significantly higher in the cyclosporine A 
(CsA)- MMF group compared to the CsA-azathioprine (AZA) group, although when 
counted only the clinical relevant lymphoceles, significance disappeared.
Pengel and Webster included all randomized studies without regard of dosages, but 
in the last 15 years there have been marked changes in dosing regimens of mTOR 
inhibitors prompted by the wound healing problems in the early years of their use. 
The review of Nashan, published only a year later, describes the newer studies with 
lower through levels than the review of Pengel. Nashan describes 19 randomized 
trials of mTOR inhibitors partly using the same references as Pengel.11 With the 
exception of two studies wound healing events have been captured only as part of 
the standard adverse event and not as a rigid part of the trial documentation. They 
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show that in virtually all studies in which a loading dose of mTOR inhibitors was used 
a significantly higher rate of wound healing events was noticed. Furthermore, studies 
using different mTOR inhibitor dosages have uniformly shown a numerically lower 
incidence of wound events in the reduced exposure group. As the experience of mTOR 
inhibitors was growing, use of loading doses became less common and targeted 
through levels declined. This led to the clinical observation of less wound healing 
problems as well as the worryingly potent antiproliferative effect of the combination 
of mycophenolate acid and mTOR inhibitors.16-19 This observation was mentioned 
by Nashan in his review but also noticed in the Orion trial and in the Symphony 
trial.17,18 In the ORION study, sirolimus with MMF showed a slightly higher rate of 
delayed wound healing compared to the sirolimus-tacrolimus regimen, although the 
difference was not marked and the sirolimus target ranges were different among 
the groups.16 Kidney transplant recipients receiving low-exposure sirolimus (4-8ng/
ml) in combination with MMF experienced an increased frequency of delayed wound 
healing and lymphocele versus calcineurine inhibitor-based regimens.17 In 2013, 
Cooper et all also tried to resolve the issue of wound healing in case of lower 
mTOR inhibitor dosages. They pooled data of three randomized controlled trials 
to look at wound healing.13 In the three trials no loading dose of mTOR inhibitors 
was given and through levels were targeted at different, but low levels (3-8 or 
6-12 ng/ml). In total 1996 patients were analyzed of which approximately one third 
received everolimus 1.5 mg/day, one third everolimus 3.0 mg/day and one third MMF, 
combined with CsA and corticosteroids. They found a significantly higher incidence 
of wound healing events in the higher dosed everolimus group compared to the 
other groups. In a multivariate analysis a progressive increase in risk was noted for 
increasing through levels of everolimus. Mehrabi et al reviewed the literature and 
described the effects of MMF, Sirolimus and mTOR inhibitors.9 The authors provide 
a useful classification of wound complications (superficial wound dehiscence, deep 
wound or fascia dehiscence, perigraft fluid collection/seroma, superficial wound 
infection, deep wound infection, cellulitis, lymphocele, prolonged wound drainage) 
and focus their review on surgical and technical factors that may be responsible for 
wound complication events. 
Drawbacks of the literature
Unfortunately the clinical problem of wound disturbance is often not classified 
and many different descriptions appear in the literature such as wound infection, 
wound dehiscence, wound drainage (clear or bloody), wound separation, wound 
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contamination, tissue necrosis and wound herniation. The reviews have included 
large studies that were aimed to test immunosuppressive agents for patient and 
graft survival, with complications as a by-product. The evidence of these trials is 
high for characteristics as graft and patient survival, early and late rejection and 
kidney function. For the aspect of wound healing, the evidence of these clinical 
trials that are not aimed nor powered to measure wound healing, might be lower 
than the evidence that we have got from smaller retrospective studies designed to 
investigate wound healing.
Retrospective clinical studies
Some retrospective studies were designed to investigate wound healing in the 
kidney transplant recipient. In 2001 Humar et all published the data of a retrospective 
analysis of 2013 kidney transplants between 1984 and 1998.4 Immunosuppression 
used was cyclosporine, azathioprine, and prednisone. In 1997 a switch was made 
from azathioprine to MMF. Wound complications were captured, both infectious and 
non-infectious. They were classified as superficial or deep, the latter meaning 
involving the fascia. In this study the infection rate was low (4.8%), 1% developed 
a deep infection. The mean time to develop a superficial infection was 11.9 days, to 
develop a deep infection 39.2 days. Recipients with infection tended to be older, 
more obese, and had more often had a re-transplantation. In multivariate analysis 
a BMI of >30kg/m2 was highly significant, but also a urine leak, any reoperation 
through the transplant incision, diabetes and the use of MMF were significant factors. 
Patient survival was significantly lower in the recipient group with a wound infection 
(65.8% versus 83.3% after 5 years). Interestingly, also death-censored graft survival 
was significantly lower in the wound infection group. (70.7% versus 81.9%), with 
more acute and chronic rejection. The authors suggest this might be the result of a 
lowering in immunosuppression in case of wound infections. Early fascial dehiscence 
or late incisional hernia were seen in 3.6% of patients. Mean time to diagnosis was 
12.8 month post transplant. Obesity, higher age, reoperation and the use of MMF 
were all very significant in multivariate analysis. The study of Troppmann et al from 
2003 dates from the time that sirolimus was investigated as a new addition to the 
immunosuppressive armamentarium.20 Immediately after introduction however, an 
increased incidence of lymfocele was noted and related to the use of sirolimus.21,22 
In the Troppmann study 15 kidney transplant recipients receiving sirolimus, 
prednisone and tacrolimus or cyclosporin (the study population) were matched an 
compared to 15 patients receiving prednisone, mycophenolate mofetil and 
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tacrolimus.20 Wound healing complication was defined as any wound complication 
that needed intervention such as re-laparotomy, seroma aspiration or incisional 
hernia repair. In the study group an appalling 53% of wound complications was noted 
which was significantly higher than the 7% of wound complications in the control 
group. A similar observation was reported by Seaman et all. who noted a surgical 
complication rate of 35% in patients receiving sirolimus vs. 4% in those not receiving 
sirolimus.23 The study population was bigger (175 patients), but they published their 
results only as abstract. In 2003 Flechner et all published a retrospective study of 
513 consecutive kidney transplant recipients from 1993 until 2002.24 They divided 
the group of 513 patients in 3 groups with different immunosuppressant regimes. 
Because of the size of the group the study population encompassed different 
transplant era, just like the Humar study of 2001. Groups were not alike in terms of 
age, insulin dependent diabetes mellitus, body mass index and induction therapy, 
but statistically correcting for all these differences they found no influence of the 
immunosuppressant regime. Individual risk factors were analyzed for their 
association to wound healing complications in an univariate model. With decreasing 
significance, the important risk factors were obesity (BMI exceeding 28), delayed 
graft function, diabetes, and recipient age greater than 50 years. The risk of wound 
healing problems correlated directly with increasing BMI. The regime of 
immunosuppressant did not make any difference. One year later, his college Goel 
published the exact same series of patients to look at the incidence of lymphocele. 
In the entire group the incidence of lymfocele was 33.9% and the incidence was 
significantly higher in the group using sirolimus, MMF and prednison.25 In the study 
of Flechner and Goel sirolimus was targeted at through levels of 10-12ng/ml. Very 
similar to the study of Flechner and Goel is the study of Langer et al, published in 
2002.22 Again, this is a retrospective analysis of patients from different 
immunosuppressive era. They compared the incidence of fluid collections in a group 
of kidney recipients treated with sirolimus, cyclosporine, prednisone (n=354) with a 
group treated with cyclosporine-prednison, with or without azathioprine (n=136). In 
the sirolimus group, three different regimens were used. The fraction of patients 
displaying perinephric fluid collections was much higher in the sirolimus group than 
in the non-sirolimus group. The time of diagnosis of a lymphocele was around 2 
months postoperatively. At the time of onset the mean sirolimus through level was 
11.3 ng/ml which was not higher than the group of sirolimus users without a 
lymphocele. The conclusions of Langer are that addition of sirolimus to a cyclosporine 
and prednisone regimen results in a higher incidence and a requirement for more 
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aggressive treatment of perinephric fluid collections and lymphoceles. In 2003 a 
retrospective study of Giessing and Budde showed an extremely high risk for 
lymphocele formation under treatment of sirolimus.26 In the years 2000 and 2001 
they analyzed 85 consecutive kidney transplant recipients using a regimen of 
sirolimus combined with cyclosporine and prednisone (13 patients), or prednison, 
MMF and cyclopsorin or tacrolimus (72 patients). Eight patients (61%) in the sirolimus 
group developed a lymphocele with a size between 70 and 800 ml. In the control 
group only one lymphocele was found which was small and asymptomatic. Target 
through levels in this study were between 5 and 15 nanogram/ml. Valente et al 
compared in 2003 retrospectively 84 kidney transplant recipients receiving MMF 
with 74 patients receiving sirolimus.27 Both groups received corticosteroids and 
tacrolimus. The latter was tapered to a target blood level of 8-12ng/ml in the MMF 
group and 5-8 ng/ml in the sirolimus group. Overall an incidence of 21.5% wound 
complications was noted. The incidence of wound complications was 2.4% in the 
MMF group and 43.2% in the sirolimus group. In a multiple logistic regression 
analysis the use of sirolimus and a low serum albumin were independent correlates 
for wound events. When only non-lymphocele wound events were analyzed also a 
high BMI was correlated to wound events. More recently investigators worried about 
the concomitant use of steroids in all studies that are executed to define the effect 
of sirolimus on wound healing. In 2005 Rogers et al compared a group of 109 
patients that were enrolled in a clinical corticosteroid avoidance trial between 2000 
and 2003 , with a historical group of 72 patients that received long-term maintenance 
corticosteroids between 1997 and 2000 to look specifically at wound complications.28 
They evaluated the possibility that sirolimus and corticosteroids have an additive 
effect on wound healing. Patients in the corticosteroid sparing group received 
induction with antithymocyte globulin, sirolimus (target through level 8-12 ng/ml), 
cyclopsorin, and MMF. The control group received cyclosporine, MMF and long term 
corticosteroids. The wound complications included lymphocele, dehiscence, diastasis, 
skin edge separations and hernia’s. Despite the use of sirolimus in the corticosteroid 
sparing group, a significantly lower incidence of wound complications was observed 
in the this group (13.7% versus 28%), primarily due to the lower incidence of 
lymphoceles. In 2006 Grim published contradictory results, in a group of patients 
that were tapered off steroids within 6 days after renal transplantation.29 Sirolimus 
was not part of the routine protocol but prescribed when patients experienced 
toxicity from another agent. They indentified the patients that had received sirolimus 
in the first 6 weeks (for more than 72 hours) and divided this group in a group with 
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and a group without complications and used a control group of patients on 
tacrolimus. The immunosuppressant regimen with sirolimus was very similar to that 
of Rogers at all. Of the 44 patients that had used sirolimus 14 (31.8%) developed 
complications such as lymphocele, bladder leak, wound dehiscence, cellulitis and 
abscess. Some patients had more than one complication. In sirolimus patients with 
BMI >30 kg/m2 the complication rate was very high (71.4%). The rate of complications 
in the tacrolimus group was less than half of the sirolimus group (14.3%), although 
this difference was not significant. Knight tried in 2007 to determine risk factors for 
wound complications after renal transplantation.30 Data were retrospectively 
collected from 263 consecutive patients who used sirolimus de novo. After excluding 
patients with early graft loss, with simultaneous pancreas transplantation and with 
incomplete follow up 194 patients remained. Induction therapy with basiliximab or 
thymoglobulin was given. Sirolimus was started on the day of operation in recipients 
of deceased donor grafts with a loading dose. Through levels were maintained at 
10-15ng/ml. For living donor recipients sirolimus was started 4 days pre-operative. 
Furthermore cyclosporin and corticosteroids were given. Patients were followed at 
least one year. Approximately one third of the patients suffered one or more wound 
complication. In the multivariate analysis, older age (above 40 years), BMI above 26, 
Caucasian race, thymoglobuline induction and cumulative use of at least 35 mg 
sirolimus in the first 4 days were related to the development of wound complications.
Prospective clinical studies
Few authors have carried out prospective studies to determine the effect of 
immunosuppressant therapy on wound healing. Following the first retrospective 
observations, Dean et all carried out a prospective cohort study in 2004.31 In a 
group of 125 patients 28% developed one or more wound events, that were 
classified as: superficial wound dehiscence, perigraft fluid collection, superficial 
wound infection, deep wound infection, cellulitis or fascial dehiscence. All patients 
received antithymocyte globuline induction and MMF. From postoperative day 4 
on, 59 patients received tacrolimus and 64 patients received sirolimus. The mean 
follow up for the group was 21 months. After one year of including the authors 
decided to exclude patients with a body mass index of more than 32 kg/m2 
because of a disproportionate number of wound healing complications in obese 
patients and to lower through levels of sirolimus from 15-20 ng/ml to 10-15 ng/
ml. After this alteration wound complications dropped from 55% to 35%. Their 
results were very clear: the use of sirolimus was very significantly related to higher 
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wound complications. Furthermore; wound complications increased concurrently 
with increase of recipient BMI in both groups. In 2009, Albano et all performed 
a prospective, multicentre, open label study with recipients of deceased-donor 
kidneys receiving everolimus therapy either from day 1 postoperative or from week 
5 postoperative.32 In the delayed group, MPA was given until everolimus was started. 
All patients received anti-interleukine-2-receptor antibodies, cyclosporine A and 
corticosteroids. No loading dose of everolimus was given and through levels of 
everolimus were aimed at 3-8 ng/ml. The objective of the study was to determine 
whether delayed introduction of everolimus would reduce the incidence of delayed 
graft function and/or wound healing disorders, while maintaining efficacy during the 
first three months post transplantation. They recruited in total 139 patients, all at 
higher risk than average for delayed graft function. Wound events were prospectively 
captured and graded slightly different than in the prospective study of Dean: fluid 
collections, wound dehiscence (superficial or deep), incisional hernia, urine leak, 
anastomotic disruption, necrosis or other. The number of wound events was similar 
in both groups for each type of event. In both groups any wound healing disorder 
was high (40 and 41.9%), mostly existing of fluid collections (87.5%). Aspiration, 
drainage or surgery did not differ between groups. Post procedural ultrasounds 
were available in three quarter of the patient-group. Peri-renal fluid collections were 
noted in 36% of patients with no difference among groups.
In 2017 Dutt et all tried to unravel the effect on woundhealing of immunosuppressants 
in kidney transplantation by taking skin-biopsies of patients that were on 
immunosuppressant therapy after renal transplantation.33 They included 40 patients 
of which half used a standard protocol containing a calcineurine inhibitor, MMF and 
prednisone and half used a protocol containing Everolmus in combination with MMF 
and prednionse, with or without a calcineurine inhibitor. Everolimus was admitted 
in a dosage of 2.5 mg per day. The skin biopsies were analyzed for homeostatic 
gene expression and showed no difference between the two groups. The wounds 
were photographed and wound area surface was measured. No delay in closure 
was noted. Finally peripheral blood mononuclear cells were examined for cytokine 
production. T-cells of everolimus-treated patients were more sensitive to cell death 
than non-everolimus treated patients, but they retained the ability to produce 
proinflammatory cytokines required for efficient wound repair. 
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Conclusion 
Recapitulating, we can state that concern about wound healing dates from the time 
that immunosuppressive agents were introduced but focus on this problem slowly 
increased, following the increase in patient and organ survival. The introduction of 
sirolimus has tremendously enhanced awareness of wound healing disturbances. 
The introduction of MMF and especially the combination with mTOR inhibitors 
renewed the interest in wound healing disturbances. Obviously, all clinical studies 
are struggling with the multitude of factors that are able to attribute to a negative 
effect on wound healing and it remains very difficult to assess the effect of a single 
agent. Technically it is very difficult to entangle the effect on wound healing in a 
clinical study, where a poly-drug study regimen is used. All the cumulating evidence 
however, has led to some modifications in clinical practice. In recent years loading 
doses of mTOR inhibitors, such as sirolimus and everolimus have been abandoned in 
the light of the wound healing complications. Also mTOR inhibitors have increasingly 
been banned from the immediate postoperative phase. In this light, it is important 
to know the effect on wound healing of each individual immunosuppressive agent 
that only can be measured in the preclinical setting.
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Abstract
Background. 
Although clinical data suggest its existence, little is known about the effect of 
rapamycin derivatives on wound repair. This study aims to delineate the influence 
of the mammalian target of rapamycin inhibitor everolimus on wound healing in 
the rat intestine. 
Methods. 
Four groups of 26 male Wistar rats received everolimus in daily oral dosages of 0 
(controls), 0.5 (group E-0.5), 1.0 (group E-1), and 3.0 (group E-3) mg/kg every 24 hours, 
respectively, starting four hours before the operation until killing. After resection 
of 1-cm segments of colon and ileum, intestinal anastomoses were constructed. 
The animals were killed at days three or seven after operation. Wound healing was 
assessed by mechanical (bursting pressure, breaking strength), biochemical (collagen 
content, gelatinase activity), and histologic parameters. 
Results. 
No differences between groups were recorded for any of the parameters on day 
three. On day seven, a dose-dependent reduction in breaking strength (P<0.05) 
was measured. The largest effects were found in group E-3 in which the breaking 
strength was reduced by 56% and 73% in colonic and ileal anastomoses, respectively. 
A similar pattern was observed with the bursting pressure. Loss of strength was 
accompanied by a reduction in hydroxyproline content and by a lessened collagen 
deposition in the wound area but not by an increased gelatinase activity. No further 
histologic abnormalities were found.
Conclusion. 
Everolimus causes a massive reduction in anastomotic strength such as normally 
observed in the proliferative phase of repair. The data suggest this to be caused by 
an impaired deposition of collagen in the anastomotic area.
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Introduction
The mammalian target of rapamycin (mTOR) is a member of the phosphoinositide 
3-kinase-related kinase family and a central modulator of cell growth and 
proliferation.1,2 It functions within the cell as a transducer of information from various 
sources, including growth factors, energy sensors, and hypoxia sensors as well as 
components of the cell regulating growth and division.3 Blocking mTOR function 
results in arrest of the cell cycle at the G1 phase of many cell types, including T- and 
B-lymphocytes, and leads to immunosuppression.3,4 The mTOR inhibitors sirolimus 
(rapamycin) and its derivative everolimus are immunosuppressants that are applied 
to prevent rejection in clinical transplantation. The use of sirolimus has led to the 
observation of wound complications in renal, hepatic, small bowel, and cardiac 
transplantation.5-10 So far, there are no clinical data on the influence of everolimus on 
wound healing, but preliminary observations suggest likewise. Everolimus is known 
to inhibit vascular endothelial growth actor function and vascular remodeling, which 
is an important mechanism in progressive allograft dysfunction. These properties, 
combined with inhibition of proliferation of fibroblasts and angiogenesis, may also 
be of influence on the proliferative phase of wound healing.11,12 There is, however, 
surprisingly little experimental evidence to delineate these hazards for wound repair. 
To study the effects of everolimus in a validated animal model that is relevant for 
clinical transplantation, an experimental study of rodent intestinal anastomotic 
healing was performed. With this model, ample experience has been gained in 
our laboratory; most recently, the effects of ischemia/reperfusion and those of 
antiinflammatory drugs have been investigated.13,14 In the current comprehensive 
study, we have examined the effects of increasing doses of everolimus on 
anastomotic healing in the rat intestine. Wound healing was assessed on both 
the third and seventh days after operation, which period covers the proliferative 
phase of repair characterized by large changes in wound strength using mechanical, 
biochemical, and histologic parameters.
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Materials and methods
Animals
Male Wistar rats (body weight 240–260 g; Harlan, Horst, The Netherlands) were 
housed two per cage and allowed to become accustomed to laboratory conditions 
for one week before the start of the experiment. All animals had free access to 
water and standard rodent chow (Hope Farms) with the exception of a 12-hour 
period before operation when they were denied chow. The institutional animal ethics 
review committee of the Radboud University approved the study.
Study Design and Surgery
One hundred four rats were randomly divided into four groups of 26 animals each. 
Three groups received everolimus (Certican; a gift from Novartis Pharma B.V.) orally 
by gavage in daily dosages of 0.5 (group E-0.5), 1.0 (group E-1), or 3.0 (group E-3) 
mg/kg every 24 hours, respectively, starting 4 hours before the operation until 
killing. The study was funded by the Radboud University Medical Center Nijmegen 
and Novartis Pharma BV, Arnhem, The Netherlands. The control (C) group received 
daily saline. All rats were operated on day 0 and half were killed at day three and 
seven each. In each group of 13, 10 animals were used for analysis of mechanical and 
biochemical parameters and three for histology. On day 0, the rats were anesthetized 
using isoflurane in a mixture of oxygen and nitrous oxide. After a midline laparotomy, 
a 1-cm resection was performed at the distal ileum, 15 cm proximal to the cecum. 
Continuity was restored by constructing an end-to-end anastomosis with eight 
singlelayer, inverting, interrupted 8–0 Ethilon (Ethicon) sutures. The same procedure 
was carried out in the descending colon, 3 cm proximal to the peritoneal reflection. 
The abdomen was closed with a 4–0 silk suture for the musculofascial layer and 
with staples for the skin. During operations, body temperature was kept at 38°C 
using a heating pad. Temperature, heart rate, and peripheral oxygen saturation 
were monitored. The intestines were covered with gauze pads soaked with 0.9% 
NaCl to minimize desiccation. To compensate for fluid loss, 10mL of 0.9% NaCl 
was administered subcutaneously during the operation. Postoperative analgesia 
was performed with buprenorphine, 0.02 mg/kg subcutaneously, twice daily 
for two days. Animals were weighed daily and observed for signs of illness. All 
operative procedures were performed by the same investigator (B.M.). Subsequent 
measurements of anastomotic strength and biochemical and histologic parameters 
were performed by investigators, who were blind as to the medication administered.
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Anastomotic Strength
Animals were killed by intracardiac puncture after anesthesia with isoflurane. 
Relaparotomy was performed and the anastomotic intestinal segments, 
approximately 4 cm in length with the suture line in the middle, were carefully 
resected, including surrounding tissues and adhesions, and washed in saline. 
Intraluminal faeces were removed. Subsequently, each anastomotic segment was 
connected to an infusion pump on one side and to a manometer on the opposite side. 
The pressure was then raised by infusion of methylene blue dissolved in saline at a 
rate of 2 mL/minute and was recorded graphically. Bursting pressure was defined as 
the maximum intraluminal pressure the segment resisted. Thereafter, the breaking 
strength was measured in the same segment with traction in a tensiometer. This 
procedure has been validated previously.15 The breaking strength was defined as the 
peak force necessary to induce disruption of the suture line. Finally, the anastomotic 
segment was carefully cleaned from adhering tissue and a 5-mm sample, with the 
suture line in the middle, was frozen in liquid nitrogen and stored at -80°C until 
further processing.
Biochemical Analysis
After lyophilization, tissue samples were weighed, pulverized, and lyophilized again. 
The hydroxyproline content, as a measure of the collagen content, was measured 
by highperformance liquid chromatography after hydrolysis with 6-N-hydrochloric 
acid and derivatization with dabsyl-chloride. Both hydroxyproline concentration 
(mg/mg tissue) and hydroxyproline content (mg/5-mm tissue) were quantitated. 
Preparation of tissue extracts and procedures for gelatin zymography have been 
described previously.16 The various gelatinase activities were quantitated on the 
basis of lysed area and expressed as arbitrary units. Comparison of values obtained 
on different gels was performed by using collagenase type I (from Clostridium 
histolyticum; Sigma Chemical) as an internal standard. The presence of true matrix 
metalloproteinase (MMP) activity was confirmed by adding 10 mmol/L EDTA or 1,10 
phenanthrolene to the buffers used after electrophoresis.
Histology
Animals to be used for histologic evaluation of the wound were killed as described 
previously. Intestinal samples of approximately 1cm length containing the 
anastomosis in the middle were carefully resected en bloc, opened at the mesenteric 
side, and washed gently in 0.9% NaCl. They were spread out and immobilized and 
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the samples were immediately fixed in 4% phosphate-buffered formaldehyde, pH 
7.3. Each anastomosis was divided into two or three longitudinal strips. Specimens 
were dehydrated and embedded in paraffin. Sections of 4 mm in thickness were 
stained with hematoxylin and eosin. Sections were analyzed in a blind fashion using 
a binocular light microscope. Histologic parameters for anastomotic repair were 
assessed as described before.17 Another set of longitudinal sections was stained 
with picrosirius red to identify collagen fibers. Collagen measurements in the 
anastomotic area were performed by digital image analysis.17 Images were recorded 
by a RGB camera (Sony DXC-950 P) mounted on a conventional light microscope 
(Zeiss Axioskop 2 plus) using a 5x objective. Image acquisition and analysis were 
performed using a complimentary software program (Zeiss KS 400 AxioVision 
3.0). Microscopic images were digitized and the area positive for picrosirius red 
staining was recognized by segmentation in RGB using fixed threshold values. 
The anastomotic area between the two inverted apposited muscular layers was 
interactively defined on the computer screen. The ratio of picrosirius red positive 
and the total amount of pixels yielded the percentual area of anastomotic collagen. 
Statistical Analysis
To analyze the statistical differences between all groups, one-way analysis of 
variance was performed followed by a Tukey-Kramer multiple comparisons test. 
Differences with P value<0.05 were considered statistically significant. Occasionally, 
other tests were used, which are mentioned in the text.
Results
All rats recovered quickly and resumed normal behavior within a few hours after 
surgery. No rats died prematurely. At relaparotomy, none of the animals showed 
signs of intraabdominal abscess formation or peritonitis. Filmy adhesions were 
common. No anastomotic dehiscence had occurred. Postoperative weight loss was 
observed in all groups from day 0 to day three. Thereafter, the animals regained 
weight, with the exception of those in the E-3 group, which resulted in a significantly 
(P<0.001) larger percentual weight loss from day four onward (Fig. 1).
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Anastomotic Strength
Wound strength after surgery was analyzed by measuring both breaking strength and 
bursting pressure in the anastomotic segments. At day three, the average breaking 
strength in the control group was 22±16g (standard deviation) in the ileum and 
117±17g in the colon, respectively. Values in the experimental groups were quite 
comparable. At day seven, the breaking strength in the control group had increased 
strongly and significantly (P<0.01, unpaired two-tailed t test) to 89±21g in the 
ileum and 189±62g in the colon. This increase in wound strength was severely 
compromised in the rats that had been treated with everolimus, most severely so 
in the group (E-3) that had received the highest dosage. Here, average breaking 
strength remained unchanged from day three to day seven: 28±16 versus 33±18g, 
respectively, in the ileum and 104±18 versus 83±29g, respectively, in the colon. As 
a result, anastomotic breaking strength at day seven was significantly reduced in 
a seemingly dose-dependent manner in almost all experimental groups (Fig. 2). A 
similar pattern was observed for the anastomotic bursting pressure. At day three, all 
ruptures occurred within the suture line, whereas no significant differences between 
groups were recorded. At day seven, again, anastomotic strength seemed increasingly 
affected with rising drug doses, resulting in significantly (P<0.05) lower bursting 
pressures in all everolimus groups in the ileum and in the E-3 group in the colon 
(Fig. 3). Also, rupture occurred more frequently within the suture line, indicating 
reduced wound strength, in the experimental groups. This was significantly (P<0.01, 
c2 test for trend) so in the colon.
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Figure 1. Course of body weight. Data represent mean±standard deviation (n=10) of relative weights 
(versus value before surgery) in the first seven days after construction of intestinal anastomoses in 
controls (●) and rats receiving increasing doses of everolimus (E-0.5: *; E-1: ∆; E-3: x). *P<0.001.
Figure 2. Anastomotic breaking strength. Data represent mean±standard deviation (n=10) on day seven 
after construction of anastomoses in ileum (white bars) and colon (black bars) in controls (C) and rats 
receiving increasing doses of everolimus (groups E-0.5, E-1, and E-3). *P<0.01 versus C, #P<0.05 versus 
E-0.5.
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Figure 3. Anastomotic bursting pressure. Individual values and means (horizontal bars) on day seven 
after surgery in ileum (upper panel) and colon (lower panel) for controls (C) and rats receiving increasing 
doses of everolimus (groups E-0.5, E-1, and E-3). Open symbols denote rupture outside the suture line 
and closed symbols rupture inside the suture line. *P<0.05 versus C, #P<0.05 versus E-1.
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Biochemical Analysis
Three days after surgery, both anastomotic hydroxyproline concentration and 
content were similar in control and experimental groups. From day three to day 
seven, these parameters increased significantly (P<0.01, unpaired two-tailed t test) 
in all groups. However, the increase appeared to be less explicit in the everolimus-
treated groups. For instance, in the colon, the average hydroxyproline content 
increased by 139% (from 128±23 to 306±114ųg/5mm) in the control group and 
only by 71% (from 107±24 to 184±45ųg/5 mm) in the E-3 group. In the ileum these 
percentages were 164 and 49%, respectively. As a consequence, both the anastomotic 
hydroxyproline concentration and content (Fig. 4A, B) were significantly reduced in 
the E-3 group. These results were also reflected in the histologic analysis (Fig. 4C, 
see subsequently). Quantitative zymography allows the detection of the latent and 
active forms of both gelatinases MMP-2 and MMP-9. At day three, anastomotic 
gelatinase activity was similar in control and experimental groups. The same was 
true for MMP-9 at day seven (data not shown). At this time point and in the colon, 
both pro- and active MMP-2 were significantly lower in the E-1 and E-3 groups than 
in the control and E-0.5 groups (Fig. 5). In the ileum, the same trend was seen, 
although less explicitly. 
Histology
A comprehensive examination of sections obtained from three rats from each group 
did not reveal the existence of any obvious architectural differences between the 
groups either at day three or at day seven. Semiquantitative analysis did not indicate 
any differences between control and everolimus-treated groups with respect to 
histologic parameters such as epithelial damage, wound area surface, degree of 
necrosis, edema, mucosal repair, or cellular infiltration.
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Figure 4. Anastomotic collagen. (A and B) Mean±standard deviation (n=10) for the hydroxyproline con-
centration and the hydroxyproline content, respectively, on day seven after surgery in controls (C) and 
rats receiving increasing doses of everolimus (groups E-0.5, E-1, and E-3). (C) Mean±standard deviation 
(n=3) for the histologic measurement of wound collagen. Black bars are anastomoses in colon and white 
bars anastomoses in ileum. *P<0.05 versus C, #P<0.05 versus E-0.5.
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Figure 5. Anastomotic matrix metalloproteinase-2 (MMP-2) activity. Data represent mean±standard 
deviation (n=10) for both pro-MMP-2 and active MMP-2 on day seven after construction of anastomoses 
in colon (A and C) and ileum (B and D) in controls (C) and rats receiving increasing doses of everolimus 
(groups E-0.5, E-1, and E-3). *P<0.001 versus C, #P<0.01 versus E-0.5.
This is illustrated in Figure 6, which gives typical examples of hematoxylin and 
eosin of anastomoses in the ileum and colon from controls and animals from group 
E-3 at day seven after surgery. Sections colored with picrosirius red were used for 
measurement of anastomotic collagen content at day seven (Fig. 4C). Although 
the numbers are insufficient to yield statistical significance, the data support 
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the biochemical data in suggesting that the anastomoses from the everolimus 
groups contain less collagen. The average percentage wound collagen in the ileal 
anastomosis in the E-3 group is 36% lower than in the control group (30±1 versus 
47±4%). In the colon thisvalue is reduced by 29% (37±7 versus 52±5%).
Figure 6. Anastomotic histology. Typical examples of hematoxylin and eosin-stained sections of sev-
en-dayold anastomoses from control animals (A, colon; B, ileum) and everolimus treated animals of 
group E-3 (C, colon; D, ileum). Each panel shows a tissue segment with the anastomosis in the middle 
and the mucosal layer on top at a magnification of approximately X40.
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Discussion
Administration of the mTOR inhibitor everolimus can severely compromise the 
restoration of strength in healing intestinal anastomoses. The loss of strength 
depends on the dose of everolimus given, from the day of surgery onward, and is 
associated with a decreased collagen content of the wound area without evidence 
for an augmented presence of proteolytic enzymes of the MMP family. So far, there 
has been no comprehensive preclinical study that describes the effects of any 
rapamycin derivative on wound healing. Dutley and coworkers have reported an 
impaired breaking strength of airway anastomoses at postoperative day 14 if pigs 
received 1.25 mg/kg per day of everolimus.18 They found no significant changes in 
the histoarchitecture, which finding corresponds to the present data showing normal 
histology. Although two very recent studies purport to demonstrate reduced strength 
of ureter and bile duct, anastomoses on the fifth day after surgery in pigs treated 
with rapamycin, the small size of the groups investigated precludes significance 
of any of the effects.19,20 The effects demonstrated here on intestinal wound 
strength are massive. Although most pronounced at the highest dose of everolimus 
used, the lower doses also show significant impairment of anastomotic strength. 
Intestinal wound healing proceeds along the phases, which are generally believed 
to be intrinsic to all forms of soft tissue repair.21,22 Anastomoses should be able to 
withstand both intraluminal and longitudinal forces. Therefore, both the bursting 
pressure and the breaking strength, which can be analyzed independently, have been 
measured with essentially similar results. The doses tested in our study are similar to 
those used, almost invariably, to elicit immunosuppressive effects in rats.23-25 A daily 
oral dose of 2.5 mg/kg reportedly leads to trough levels of approximately 20 ng/
ml.23 In patient studies, target trough levels are almost invariably 3 to 8 ng/ml,26,27 
although Kovarik et al. 26 stated that “an upper therapeutic concentration limit is 
likely more than 15 ng/ml.” Thus, the dose range investigated by us is meaningfull 
in relation to clinical practice. Immediate postoperative wound strength mainly 
depends on the ability of existing extracellular matrix components, particularly 
collagen fibers, to retain sutures. Proteolytic degradation of the matrix, involving 
enzymes from the MMP family, is an intrinsic feature of repair.28 In the intestine, 
MMP-2 and -9 activities are significantly increased in the anastomotic area shortly 
after surgery.29 An exaggerated presence of such enzymes could lead to matrix 
degradation and loss of wound strength. We have no evidence that such is the 
case in the everolimus-treated rats. On the contrary, MMP-2 activity appears to 
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be significantly reduced in the colonic anastomoses. It thus seems unlikely that 
everolimus administration leads to matrix degradation. After an initial period, 
consisting of a few days, in which wound strength remains low, the next phase of 
healing is normally characterized by restoration of strength to the levels observed 
in uninjured tissue. Fibroblast collagen synthesis and deposition of new collagen 
fibers are essential to this proliferation phase. An intact cellular immune response, 
particularly of T-lymphocytes, is not necessary for the initial phase of wound healing 
but seems to be essential for a normal outcome of tissue repair.30 On day seven 
after surgery, anastomotic samples contain significantly less collagen if rats are 
treated with everolimus. Most likely, everolimus interferes with cellular proliferation 
necessary for normal wound repair.31,32 In particular, impaired fibroblast proliferation 
will lead to an inadequate deposition of new collagen necessary to bridge the suture 
line. The results of the present study resemble those of our earlier experiments 
with the proliferation inhibitor 5-fluorouracil33, although the effects of everolimus, 
certainly in the E-3 group, appear even more pronounced. Both drugs appear to 
affect similar mechanisms. For 5-fluorouracil, we have demonstrated subsequently 
that delay of its administration until the third postoperative day will prevent its 
negative influence on anastomotic repair.34 It would be interesting, and possibly of 
importance to clinical practice, to investigate if the negative effects of everolimus 
can also be prevented by delaying its administration and if so, to establish the first 
day that it can be given after surgery without harming the repair sequence. The 
efficacy of everolimus in combination with cyclosporine and corticosteroids in the 
prevention of rejection in de novo renal transplant recipients has been established 
in two large multicenter studies.35,36 Wound complications were not specifically 
addressed in these studies, but lymphoceles seemed to occur more frequently in 
patients treated with everolimus as compared with those receiving mycophenolate 
mofetil. There are more clinical data on wound healing under the influence of the 
mTOR inhibitor sirolimus. In a randomized comparison of sirolimus and tacrolimus, 
both combined with mycophenolate mofetil and corticosteroids, Dean and coworkers 
found a significantly increased incidence of wound-healing complications such as 
perigraft fluid collections, superficial wound infections, and incisional herniae in 
renal allograft recipients.37 These findings were in accordance with the observations 
of several other investigators.5,6 Higher rates of wound complications such as hernias 
and fascial dehiscences have also been recorded in liver, intestinal, and cardiac 
transplant recipients receiving sirolimus.7-10 Because mTOR inhibitors are in clinical 
practice invariably used in combination with other immunosuppressive agents 
3
such as corticosteroids, mycophenolate mofetil, and calcineurin inhibitors, further 
studies on the effects of these various combinations on wound healing are needed 
to delineate their hazards for wound repair. Also, the effects of timing of drug 
administration in the postoperative period should be further investigated as a means 
to develop protocols that do not constitute hazards for wound healing. 
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Abstract
The introduction of mTOR-inhibitors in transplantation surgery has been associated 
with an increase in wound complications. We have previously reported a massive 
negative effect of everolimus on anastomotic strength in rat intestine at 7 days 
postoperatively. Because it is clinically important to know if this effect persists 
and occurs generally, repair in both intestine and abdominal wall has been 
investigated over a period of 4 weeks. Wistar rats received a daily dose of 1 or 
2 mg/kg everolimus orally, from the operation day onwards. Controls received 
saline. In each rat a resection of ileum and colon was performed, and end to end 
anastomoses were constructed. On day 7, 14, and 28 the animals were killed and 
anastomoses and abdominal wall wounds were analyzed, wound strength being the 
primary parameter. Breaking strength of ileum, colon, and fascia was consistently 
and significantly reduced in the experimental groups at all time points. Anastomotic 
bursting pressures followed the same pattern. Loss of strength was accompanied 
by a decrease in hydroxyproline content after 7 days. Thus, the negative effect of 
everolimus on wound repair persists for at least 4 weeks after operation in this 
rodent model. This protracted effect may have clinical consequences and cause 
surgical morbidity. 
Introduction
The number of patients receiving solid organ transplantation is ever increasing. 
As a consequence, there is a growing number of people who depend on 
immunosuppressive drugs for transplant survival, not only immediately after 
operation but also in the long term. Therefore, efforts are aimed at improving 
immunosuppressive drugs and establish optimal regimens for both purposes. 
Sirolimus is a lipophilic macrocyclic lactone antibiotic produced from Streptomyces 
hygroscopicus which binds to the mammalian target of rapamycin (mTOR) and blocks 
its function.1 Inhibition of mTOR-mediated pathways results in arrest of the cell 
cycle at the G1 phase in various cell types, including T- and B-lymphocytes, and thus 
constitutes a potent immunosuppressive tool. Everolimus, a more recently developed 
mTOR inhibitor, is very similar to sirolimus in its pharmacodynamic effects.2 
Although rapamycin (sirolimus) was already discovered in the 1970s, interest in its 
use in transplantation surgery originated only a decade ago. The purpose of using 
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mTOR inhibitors was minimizing cyclosporine exposure and avoidance of steroids, 
because of the relatively strong side effects of the latter drugs. Addition of an mTOR 
inhibitor to the polydrug posttransplantation regimen seemed promising, but now 
that sufficient clinical experience has been gathered, they appear to induce their own 
specific adverse effects. The most important clinical side effect recognized so far is a 
negative influence of mTOR inhibitors on wound repair. For instance, wound healing 
disorders were seen in 7–53% of renal transplantation patients and rapamycin 
derivatives (e.g., sirolimus) seem to play an important role.3-7 The same phenomenon 
is noted in cardiac transplant recipients.8,9 For the transplant recipient, suboptimal 
wound healing can lead to serious complications and therefore an understanding of 
the contribution of the individual drugs in this respect is essential and can only be 
gained from experimental studies. Sound preclinical data on the effects of sirolimus 
on wound repair are only sparsely available, while nothing is known of everolimus, 
the mTOR inhibitor that has been the last in line to become available. Recently, 
we have described a strong, dose-dependent negative effect of everolimus on the 
healing of intestinal anastomoses in a rodent model. The negative effect on wound 
strength became apparent after the third postoperative day and was followed to the 
seventh day, at which point wound strength was still decreased compared with the 
control group.10 This observation raises the clinically very relevant question if the 
disturbance of wound healing by everolimus is an early and transient effect or if it 
extends over a longer period of time, thereby presumably increasing the chances 
for wound complications even further. Here, we have followed wound repair for 4 
weeks after operation. Apart from the anastomoses in ileum and colon, laparotomy 
wounds in the abdominal fascia have also been analyzed, in order to demonstrate 
that the effect is not limited to the intestine but found universally.
Methods
Animals
Male Wistar rats (body weight 240–260g; Harlan, Horst,the Netherlands) were 
housed two per cage and allowed to become accustomed to laboratory conditions 
for 1 week before the start of the experiment. All animals had free access to water 
and standard rodent chow (Ssniff Specialdiä ten GmbH, Soest, Germany). The study 
was approved by the institutional animals ethics review committee of the Radboud 
University Nijmegen.
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Study design and surgery 
One hundred forty-four rats were randomly divided into three groups of 48 animals 
each. Two groups received everolimus (Certican, a gift from Novartis Pharma BV, 
Arnhem, the Netherlands) orally by gavage in daily dosages of 1.0 (group E-1) and 
2.0 (group E-2) mg/kg, respectively, starting 4 hours before the operation until 
termination of the experiment. A control group (group C) received the same volume 
of saline daily. All rats were operated on day 0 and 16 animals from each group were 
killed on postoperative days 7, 14, and 28, respectively, for analysis of wound healing. 
From each group of 16 animals, 10 were destined for biomechanical and biochemical 
analysis and six for histology. On day 0, the rats were anesthetized using isoflurane 
3%, in a 1:1 mixture of O2 and N2O. After a midline laparotomy, a resection of 1 
cm of both ileum and colon was performed at 15 cm proximal to the ileocecal 
junction and 3 cm proximal to the rectal peritoneal reflection, respectively. End-to-
end anastomoses were constructed with eight single-layer, inverting, interrupted 
8-0 Ethilon (Ethicon, Somerville, NJ) sutures. The abdominal wall was closed with 
an absorbable, polygalactin 3-0 suture, the skin was closed with staples. A heating 
pad was used to maintain body temperature at 38 ˚C. The intestines were covered 
with gauze pads soaked with 0.9% NaCl to minimize desiccation. To compensate 
for fluid loss, 10mL of 0.9% NaCl was administered subcutaneously during the 
operation. Postoperative analgesia was performed with buprenorphine, 0.02 mg/
kg subcutaneously, twice daily for 2 days. The animals were weighed daily and 
observed for signs of illness. All operative procedures were performed by the same 
investigator (M.C.M.W.).
Biomechanical analysis 
At the designated times the animals were killed by intracardiac puncture and 
hemorrhage under general anesthesia. Relaparotomy was performed by excision of 
a part of the abdominal wall of approximately 4 by 4 cm, including the suture line 
of the fascia. Anastomotic intestinal segments, approximately 4 cm in length with 
the suture line in the middle, were carefully resected, including surrounding tissues 
and adhesions, and washed in saline. Each anastomotic segment was connected 
to an infusion pump on one side and to a manometer on the opposite side. The 
pressure was then raised by infusion of methylene blue dissolved in saline at a 
rate of 2 mL/min. Bursting pressure was defined as the maximum intraluminal 
pressure the segment resisted. Thereafter, the breaking strength was measured in 
the same segment with traction in a tensiometer. This procedure has been validated 
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previously.11 The breaking strength was defined as the peak force necessary to 
induce disruption of the suture line. From each segment of the abdominal wall, two 
separate strips of 1 by 2 cm were cut out, with the fascia suture line in the middle, 
and the breaking strength was measured in both. After biomechanical analysis, 
segments were cleaned from adhering tissue and standard sized samples containing 
the suture line were frozen in liquid nitrogen and stored at -80 °C until further 
processing. 
Collagen content 
After lyophilization, tissue samples were weighed, pulverized, and lyophilized again. 
The hydroxyproline content, as a measure of the collagen content, was measured 
by high-performance liquid chromatography after hydrolysis with 6-N-hydrochloric 
acid and derivatization with dabsyl chloride. 
Histology 
Intestinal samples of approximately 1-cm length and containing the anastomosis in 
the middle were fixed in 4% phosphate-buffered formaldehyde, pH 7.3, immediately 
after harvesting. Each anastomosis was divided into two or three longitudinal 
strips. Specimens were dehydrated and embedded in paraffin. Sections of 4mm in 
thickness were stained with hematoxylin and eosin and a semiquantitative analysis 
of epithelial damage, wound area surface, degree of necrosis, edema, bridging 
submucosal-muscular layer, and presence of neutrophils and macrophages was 
carried out. In addition, another set of sections was stained with picrosirius red to 
identify collagen fibers. Collagen measurements in the wound area were performed 
by digital image analysis.12 Images were recorded by an RGB camera (Sony DXC-950 P, 
Sony Corporation, Tokyo, Japan) mounted on a conventional light microscope (Zeiss 
Axioskop 2 plus, Carl Zeiss BV, Sliedrecht, the Netherlands), using a x5 objective. 
Image acquisition and analysis were performed using a complimentary software 
program (Zeiss KS 400s). Microscopic images were digitized and the area positive for 
picrosirius red staining was recognized by segmentation in RGB using fixed threshold 
values. The ratio of picrosirius red positive and the total amount of pixels yielded 
the percentual area of anastomotic collagen.
Statistical analysis 
To analyze the statistical differences of the postoperative weight between all groups, 
a one-way analysis of variance was performed followed by a Tukey–Kramer multiple 
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comparisons test. For comparisons of the healing parameters the differences 
between each of the two experimental groups and the control group were analyzed 
with a onesided unpaired t-test with Welch correction. Differences with p-value < 
0.05 were considered statistically significant.
Results
Seven rats died prematurely, four in group E-2, two in group of E-1, and one in 
the control group. The latter animal died immediately after operation due to 
hypothermia. The other rats died between the second and 13th  postoperative 
day. A postmortem examination revealed no signs of anastomotic dehiscence and 
no apparent cause of death. The remaining rats recovered quickly and resumed 
normal behavior within 48 hours. All animals experienced a transient weight loss of 
approximately 10% of their body weight. From day 4 onwards all animals regained 
weight. However, the weight gain in animals receiving everolimus was less than 
the control group. This effect was consistent up to 28 days postoperatively, dose-
related and significant (p < 0.001) after 28 days (Figure 1). The difference was caused 
by a prolonged period of malaise, noted by a longer period of loss of appetite and 
piloerection in the experimental groups. At relaparotomy there were no signs of 
peritonitis or anastomotic dehiscence and filmy adhesions were common.
Figure 1 Course of body weight. Data represent mean and standard deviation (n=10) of relative weights 
(vs. value before surgery) during 4 weeks after surgery: ● control group;  E-1 group; ∆ E-2 group.
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Wound strength
Wound breaking strength of fascia, ileum, and colon is summarized in Figure 2. 
The mean breaking strength of fascia after 7 days was 62±19g (SD), which was 
significantly higher than in the experimental groups. At 14 and 28 days the mean 
breaking strength of the control group had increased further. The breaking strength 
of the experimental groups did increase as well, but far less so than in the control 
group, resulting in a significantly lower strength than in the control group at all 
measuring points. Average breaking strength of the control ileum anastomoses 
at day 7 was 93±32g and increased during the entire experimental period. Again, 
the experimental groups showed a slower development of wound strength. After 
28 days, the reduction was most pronounced, the E-1 and E-2 groups displaying a 
44% and 53% lower breaking strength, respectively, than the control group. The 
breaking strength of the colon anastomoses after 7 days was 251±35g in the control 
group and significantly lower in the experimental groups (control vs. E-1 as well 
as vs. E-2: p < 0.0001). At 14 days this pattern was the same but after 28 days only 
the strength in the E-1 group was significantly lower than in the control group. The 
individual bursting pressure data for ileum and colon anastomoses are summarized 
in Figure 3. The mean bursting pressure of the ileum after 7 days in the control 
group (240±81mmHg) did not significantly differ from that in the E-1 group, but was 
significantly (p=0.006) higher than that in the E-2 group. No significant differences 
were measured at 14 days, but a very strong effect was measured after 28 days 
(Control vs. E1 and E2 groups: p=0.0003 and 0.0025, respectively). In the colonic 
anastomoses maximum differences between control and experimental groups were 
found at 14 days (Control vs. E1 and E2 groups: p=0.0008 and 0.0002), while after 4 
weeks bursting pressure was similar in all groups. Figure 3 shows that, in a number of 
cases, the bursting site was outside the true wound area. The anastomosis has grown 
stronger than the surrounding tissue and bursting pressure value thus represents a 
minimal value. The fact that anastomoses were weaker in the everolimus groups is 
also illustrated by the fact that the percentage of anastomoses that ruptured outside 
the suture line was always lower than in the controls. For instance, after 7 days in 
the colon, these percentages were 100 for controls, 60 for the E-1 group and 33 
(p=0.003 vs. controls, Fisher’s exact test) for the E-2 group (Table 1). 
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Figure 2 Wound breaking strength. Data represent mean and standard deviation (n=10) for fascia 
wounds (A), ileal anastomoses (B), and colonic anastomoses (C). White bars: control groups; gray bars: 
E-1 groups; black bars: E-2 groups. * p < 0.05 vs. control group.
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Figure 3 Anastomotic bursting pressure. Individual values and medians (horizontal lines) in ileum (A) 
and colon (B) for controls (C) and groups receiving everolimus (E-1 and E-2). Open symbols denote 
rupture outside the suture line and closed symbols rupture inside the suture line.
Table 1. Numbers represent the number of times that rupture occurred outside the suture line vs. the 
total number of observations.
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Collagen and histology
The hydroxyproline content (mg/5mm) is used as a measure for total collagen. In 
the ileum the anastomotic hydroxyproline content in the experimental groups was 
significantly lower than in the controls after 7 and after 28 days (Figure 4). After 
7 days, the same pattern was seen in the wound samples from fascia and colon. 
However, such a decrease in hydroxyproline content was absent in fascia or colon 
at 28 days. Quantitative morphology of collagen fibers in the histological slides 
shows the same trend, although less explicitly so (Figure 5). After 7 days, the average 
percentage of wound collagen in fascia and ileum was reduced in the experimental 
groups, though not significantly. After 28 days postoperatively, no decrease in wound 
collagen was observed. Figure 6 shows examples of the picrosirius red coloring of 
fascia tissue at 7 days and colon anastomotic tissue at 28 days. A comprehensive 
histological examination of sections obtained from rats from each group did not 
reveal the existence of any obvious architectural differences between the groups 
in either intestine or fascia at any of the time points. 
Figure 4. Wound hydroxyproline content. Data represent mean and standard deviation (n=10) in fascia 
wounds (A), ileal anastomoses (B), and colonic anastomoses (C). White bars: control groups; gray bars: 
E-1 groups; black bars: E-2 groups.*p < 0.05 vs. control group.
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Figure 5. Wound collagen content. Data represent mean and standard deviation for the histological 
evaluation of wound collagen in fascia wounds (A), ileal anastomoses (B), and colonic anastomoses (C). 
White bars: control groups (n55 at day 7 and n56 at day 28); gray bars: E-1 groups (n=4 at day 7 and n=6 
at day 28); black bars: E-2 groups (n=6).
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Figure 6. Picrosirius red coloring. A=fascia control group at 7 days, B=fascia E2 group at 7 days, C=colon 
anastomosis control group at 28 days (with a piece of suture in the sample), D=colon anastomosis E2 
group at 28 days.
Discussion
The current data show the existence of a considerable and protracted impairment 
of wound healing induced by the administration of the mTOR inhibitor everolimus. 
The effect on the development of wound strength persists for at least 4 weeks after 
operation and is present in both tissues investigated, intestine and the abdominal 
fascia. Previously, we have reported the compromised restoration of strength in 
healing intestinal anastomoses of the rat as measured at day 7 after operation.10 
Both breaking strength and bursting pressure are measures for anastomotic strength 
in the intestine, yielding essentially different information. They represent the ability 
of the suture line to withstand longitudinal and intraluminal forces, respectively. It 
should be noted that here both parameters show similar trends, thereby fortifying 
the general picture of impaired strength. We have now included an analysis of the 
breaking strength of the suture-line in the anterior fascia of the abdominal wall 
as well. One reason to include these measurements is that a systemic effect of an 
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immunosuppressant drug probably would affect multiple tissues and that addition 
of such data allows more generalized conclusions. Also, healing disorders of the 
abdominal wall are responsible for a large body of surgical complications observed 
in kidney transplantation patients. The effects of everolimus on fascia and bowel 
wall strength are similar, which strongly suggests that everolimus is responsible 
for a generalized negative effect on wound repair. In addition, the data support 
the concept that this model indeed reflects the clinical increase in wound healing 
complications such as seroma or herniae, commonly found in patients after kidney 
transplantation who are treated with immunosuppressant drugs, in particular mTOR 
inhibitors. The doses of everolimus we have chosen are based on the dose range used 
in our previous study10 and similar to those used to elicit immunosuppressive effects 
in rats.13-15 Daily oral doses of 1 or 2.5 mg/kg are expected to result in trough levels 
approximating 6 and 8 ng/mL, respectively.16,17 In patient studies, target trough levels 
are usually between 3 and 15 ng/mL,18 although an upper therapeutic concentration 
limit is likely to exceed 15 ng/mL.19,20 Thus, the doses used are clinically relevant 
in terms of the human therapeutic range. Others have investigated the effects of 
mTOR inhibitors on wound repair, though not those of everolimus.21-24 Published data 
concern other tissues and analysis of repair is mostly restricted to one time point 
only. Very recently, Wagner and coworkers have concluded that sirolimus does not 
impair the healing of bowel anastomoses, in seeming contradiction to data reported 
earlier by us for everolimus.10 However, these authors based their conclusion on an 
experiment with colon anastomoses that lasted only 4 days.25 Proliferation inhibitors 
such as sirolimus and everolimus are logically thought to affect the proliferative 
phase of wound healing, which starts around the third postoperative day. It is 
therefore very likely that their effects only become apparent somewhat later, for 
instance at day 7. Indeed, in our previous study no effects were observed at day 
3, and severe effects at day 7, emphasizing the dangers of drawing generalized 
conclusions on the basis of measuring at one time point only. The maximum duration 
of preclinical studies of mTOR inhibitors is 15 days.22,26 Transplant patients receive a 
lifelong immunosuppressive drug regimen from the day of their operation onwards 
and a prolonged disturbance of wound repair may have clinical consequences and 
cause surgical morbidity. For this reason we have extended our observations to 28 
days, in order to determine if at that time point initial suppression of wound repair 
would be compensated for, even during continued use of everolimus. However, 
the data prove a lasting negative effect on wound strength that, in the ileum and 
fascia, even outlasts the duration of the experiment. Wound strength depends 
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on the extracellular matrix, more specifically on the structural protein collagen. 
Several mechanisms of action can, exclusively or in combination, be responsible for 
the negative effects of everolimus. A prolonged proliferation phase, deposition of 
insufficient collagen or collagen of inferior structural quality, and even disturbance 
of the remodeling phase may play a role. After 7 days, the wound hydroxyproline 
content in the experimental groups is less than that in the control group. This is a 
consistent finding and probably constitutes the main reason for a weaker wound 
long after operation.10 However, after 28 days the hydroxyproline content in colonic 
anastomoses and fascia in the everolimus groups is restored to normal levels, or 
even exceeds them, while at the same time wound strength in all tissues still lags 
behind the control group. Although the results of the histological determination of 
collagen does not yield significant differences between control and experimental 
groups, which might be due to the limited number of observations, the qualitative 
pattern appears the same. One should realize that the data on wound collagen, 
obtained by histomorphometry, represent the true wound area, while those obtained 
by hydroxyproline measurements represent a tissue sample of 5mm length with the 
wound in the middle. The latter thus contains some degree of adjacent tissue and 
this may explain the apparent difference in outcome between the two separate 
methods. Therefore, the conclusion that diminished strength is caused exclusively by 
a decrease in quantity of collagen is not justified. In other experimental studies that 
have addressed the mechanism of action of mTOR inhibitors, reduced inflammatory 
cell numbers are evident, while hydroxyproline levels are not consistently 
decreased.24,27 Also, sirolimus treatment leads to a decreased expression of vascular 
endothelial growth factor and nitric oxide, mediators of angiogenesis and immune 
function, in skin wounds.24 More research is thus needed to determine the exact 
mechanisms of everolimus on wound healing. In conclusion, the potentially negative 
effects of mTOR inhibitors on wound healing gradually have become evident over 
the last couple of years and should be well recognized. Still, mTOR inhibitors may 
possess certain benefits over other immunosuppressive agents such as calcineurine 
inhibitors, not in the least because of the absence of nephrotoxicity in transplant 
patients. With a delay in administration of mTOR inhibitors, until wound healing 
is completed or the development of wound strength well under way, we might be 
able to combine advantages and disadvantages. Such an approach may optimize 
posttransplant medication regimens and further reduce surgical complications 
thereby improving transplant and patient survival. 
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Abstract
Background.
The use of mTOR inhibitors coincides with an increased incidence of surgical 
complications. In previous experiments serious negative effects of postoperative 
everolimus on anastomotic strength were found. This study aims to investigate if 
delayed drug administration can prevent loss of wound strength.
Methods.
Ten groups of Wistar rats each received daily oral doses of 1.0 or 2.0 mg/kg 
everolimus, starting the day of anastomotic construction in both ileum and colon, 
or 1, 2, 3 or 4 days later. The eleventh group received saline. Seven days later wound 
strength in anastomoses and in the abdominal wall and wound hydroxyproline 
levels were measured. 
Results.
Mean wound strength was significantly and dose-dependently reduced if everolimus 
was started on the day of operation. In ileum and colon strength was not affected 
if drug administration was delayed until the third or second day, respectively. In 
abdominal fascia this was the case only if everolimus was withheld until day 4. In 
general, changes in wound hydroxyproline content showed similarities to changes 
in wound strength.
Conclusion.
Thus, delaying administration of everolimus for 2-4 days after operation can prevent 
a serious loss of wound strength, both in the intestine and in the abdominal fascia. 
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Introduction
Since short-term solid organ transplant survival has improved during the last two 
decades due to advanced immunosuppressive drugs and better regimens, research 
is now aimed mostly at long-term patient and transplant survival. Rapamycin 
derivatives constitute a relatively new class of immunosuppressive drugs. They 
bind to the same intracellular binding protein as tacrolimus, but instead of inhibiting 
calcineurin, the complex blocks the function of the mammalian target of rapamycin 
(mTOR).1,2 Inhibition of mTOR mediated pathways results in arrest of the cell cycle 
in various cell types, including T-and B-lymphocytes, and thus constitutes a potent 
immunosuppressive tool. The most familiar of these mTOR inhibitors are sirolimus 
and everolimus which are very similar in their pharmacodynamic effects and 
are powerful clinical therapeutics administered for the prophylaxis of allograft 
rejection.2
The introduction of mTOR inhibitors to the poly-drug post-transplantation regime 
has led to an apparent increase in wound related complications.3-12 This constitutes 
a serious clinical problem, not only in the immediate post-transplantation period 
but also in patients who need further surgery while still on immunosuppressive 
drugs. Recently, we have demonstrated that everolimus, administered as a single 
drug from the day of operation onwards, strongly interferes with the restoration of 
tissue strength in wounds of the intestinal tract and abdominal wall in the rat.13,14 
The early gain in wound strength normally observed is essential to undisturbed 
healing as weaker wounds presumably lose their structural integrity more easily, 
resulting in dehiscence and other possible complications. It is a clinically relevant 
question whether the negative effect of everolimus can be avoided by delaying the 
start of drug administration. The current study has been designed to investigate 
whether a short postponement of one to four days would normalize the strength 
of experimental bowel anastomoses and laparotomy wounds.
Materials and Methods
Animals
Male Wistar rats (body weight 240-260 g; Harlan, Horst, The Netherlands) were 
housed two per cage and allowed to become accustomed to laboratory conditions 
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for one week before the start of the experiment. All animals had free access to water 
and standard rodent chow (Ssniff Specialdiäten GmbH, Soest, Germany). The study 
was approved by the institutional animal ethics review committee of the Radboud 
University Nijmegen.
Study design 
Rats (n=133) were randomly divided into 11 groups of 12 animals each (the E1-1 
group, see below, contained 13 animals). Everolimus (Certican; a gift from Novartis 
Pharma B.V., Arnhem, the Netherlands) was administered orally by gavage once 
daily until the end of the experiment at the 7th postoperative day. In five groups 
rats were started on everolimus at the day of operation (day 0) or at day 1, 2, 3 or 
4 after operation, in a daily dose of 1 mg/kg. These groups are named E1-0, E1-1, 
E1-2, E1-3 and E1-4, respectively. Five other groups received everolimus in a daily 
dose of 2 mg/kg, starting at similar time points, and are designated as E2-0, E2-1, 
E2-2, E2-3 and E2-4, respectively. At the days that the animals in these experimental 
groups did not receive everolimus they were administered saline. The control group 
received saline by gavage daily from the day of surgery onward. 
Surgery
The rats were anesthetized using isoflurane 3%, in a mixture of oxygen and nitrous 
oxide. After a midline laparotomy, a resection of 1 cm of both ileum and colon was 
performed at 15 cm proximal to the ileocaecal junction and 3 cm proximal to the 
rectal peritoneal reflection, respectively. End-to-end anastomoses were constructed 
with 8 single-layer, inverting, interrupted 8-0 ethilon (Ethicon, Johnson and Johnson 
Medical B.V., Amersfoort, the Netherlands) sutures. The abdominal fascia was closed 
with a running absorbable, polygalactin 3-0 suture, the skin was closed with staples. 
A heating pad was used to maintain body temperature at 38°C. The intestines 
were covered with gauze pads soaked with 0.9 % NaCl to minimize desiccation. To 
compensate for fluid loss, 10 ml of 0.9 % NaCl was administered subcutaneously 
during the operation. Postoperative analgesia was performed with buprenorphine, 
0.02 mg/kg subcutaneously, twice daily for two days. The animals were weighed 
daily and observed for signs of illness. All operative procedures were performed 
by the same investigator (MW). At day 7 all rats were killed for analysis of wound 
healing. Two animals from each group were used for histology and the others for 
measurements of strength and hydroxyproline.
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Biomechanical analysis
The animals were killed by CO/CO2 asphyxiation. Relaparotomy was performed by 
excision of a part of the abdominal wall of approximately 4 by 4 cm, including 
the suture line of the fascia. Anastomotic intestinal segments, approximately 4 
cm in length with the suture line in the middle, were carefully resected, including 
surrounding tissues and adhesions, and washed in saline. Each anastomotic segment 
was connected to an infusion pump on one side and to a manometer on the opposite 
side. The pressure was then raised by infusion of methylene blue dissolved in saline 
at a rate of 2 ml/min. Bursting pressure was defined as the maximum intraluminal 
pressure the segment resisted. Thereafter, the breaking strength was measured in 
the same segment with traction in a tensiometer. This procedure has been validated 
previously.15 The breaking strength was defined as the peak force necessary to 
induce disruption of the suture line. From each segment of the abdominal wall, two 
separate strips of 1 by 2 cm were cut out, with the suture line in the middle, and the 
breaking strength was measured in both. After biomechanical analysis, segments 
were cleaned from adhering tissue and standard sized samples containing the suture 
line were frozen in liquid nitrogen and stored at -80°C until further processing.
Hydroxyproline content and histology 
After lyophilisation, tissue samples were weighed, pulverized, and lyophilized again. 
The wound hydroxyproline content, as a measure of the collagen content, was 
measured in the control and E2 groups by high-performance liquid chromatography 
after hydrolysis with 6-N-hydrochloric acid and derivatization with dabsyl-chloride. 
Intestinal samples of approximately 1-cm length and containing the anastomosis in 
the middle were fixed in 4% phosphate-buffered formaldehyde, pH 7.3 immediately 
after harvesting. Each anastomosis was divided into two or three longitudinal strips. 
Specimens were dehydrated and embedded in paraffin. Sections of 4 mm in thickness 
were stained with haematoxylin and eosin. Another set of sections was stained with 
picrosirius red to identify collagen fibres.14
Statistical Analysis
Pairwise comparisons of groups were performed using a one-tailed (in the case of 
the hydroxyproline data: two tailed) Mann Whitney test using a level of significance 
of 2α/k where k is the number of pairwise comparisons. This way, comparison of 
the 10 experimental groups with the control group yields a significant difference 
if P<0.01. 
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Results
All rats recovered quickly and resumed normal behaviour within 48 hours. At 
relaparotomy no signs of peritonitis or anastomotic dehiscence were found and 
filmy adhesions were common. All animals experienced a transient weight loss of 
approximately 10% of their body weight. From day 4 onwards they regained weight, 
those in the control group approximating their pre-operative weight at day 7. (figure 
1) However, the weight gain in animals receiving everolimus appeared less than in 
the control group, especially so in the E2-groups. At day 7, the relative body weight 
in the E1-0 and E1-2 groups and all the E2-groups was significantly lower than in 
the control group. (P<0.01)
Figure 1. Course of body weight. Data represent mean values of relative weights (vs. value before surgery) for 
low dose (A: E1-groups) and high dose (B: E2-groups) everolimus. Animals are treated with saline (- = control 
group) or drug administration is started on day 0 (+), 1 (), 2 (), 3 () or 4 () after operation.
Wound strength
Wound strength of the fascia is summarized in figure 2. The mean breaking strength 
of fascia in the controls after 7 days was 76 ± 9g (SE), which was reduced by 41 
and 54 %, respectively, in the E1-0 and E2-0 groups. In the lower dose group, no 
significant differences with the controls were observed any more if administration 
was delayed until the second day after operation. However, among the higher doses 
this was the case only for the E2-4 group. 
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Figure 2. Fascia breaking strength. Data represent mean and standard error of the mean (n=10) for the 
control group (black bar), low dose everolimus groups (white bars) and high dose everolimus groups (black 
and white checked bars). : p < 0.01 and (): p = 0,01- 0.05 vs control group.
Breaking strength of the intestinal anastomoses is shown in figure 3. Mean breaking 
strength of the control ileum anastomoses was 99 ± 15g (SE), which was reduced 
by 35 and 50%, respectively, in the E1-0 and E2-0 groups. If administration was 
postponed until the second postoperative day, no loss of strength was observed 
any more. Anastomotic breaking strength in the colon (figure 3B) showed a pattern 
quite similar to that in the ileum. 
Another, independent, parameter for anastomotic strength is the bursting pressure, 
which is represented in figure 4. In the ileum, anastomotic bursting pressure was 
reduced significantly by both doses of everolimus, unless administration was delayed 
until the third day after operation (figure 4A). Everolimus had less effect on the 
colonic bursting pressure (figure 4B). Only for the high dose, there was a nearly-
sgnificant (p=0.0315) loss of strength, as compared to the controls, if it was given 
from the day of administration onwards (the E2-0 group).
With respect to the measurement of the bursting pressure, the location of the 
bursting site is very relevant. If rupture occurs outside the suture line the anastomosis 
has grown stronger than the surrounding tissue and the bursting pressure only 
represents a minimal value for anastomotic strength. A shift in bursting site from 
outside to within the suture line therefore also reflects loss of strength. Indeed, 
this phenomenon is observed in the everolimus groups (figure 4), significantly so if 
the higher dose is used. 
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Figure 3. Anastomotic breaking strength. Data represent mean and standard error of the mean (n=10) 
in ileum (A) and colon (B) for the control group (black bar), low dose everolimus groups (white bars) 
and high dose everolimus groups (black and white checked bars). : p < 0.01 and (): p= 0.01- 0.05 
vs control group.
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Figure 4. Anastomotic bursting pressure. Individual values and medians (horizontal lines) in ileum (A: low 
dose everolimus groups, B: high dose everolimus groups) and colon (C: low dose everolimus groups, D: 
high dose everolimus groups). Open symbols denote rupture outside the suture line and closed symbols 
rupture inside the suture line. : p < 0.01 and (): 0.01 < p < 0.05 vs control group.
Collagen and histology
The hydroxyproline content was determined as a measure for collagen quantity 
in controls and the high dose groups (figure 5). Using individual values for each 
rat, there was no correlation between wound hydroxyproline content and wound 
strength. If mean values were taken, the differences in wound hydroxyproline 
content between groups showed similarities to those in strength. Although not 
always significant, average values tended to be lowered in the E2-0 and E2-1 groups 
and to be restored in the E2-4 groups. To some extent, this trend was also found in 
the histological data, although they were obtained for 2 rats only in each group. For 
instance, the percentual area for wound collagen was 52, 44 and 45% in the control, 
E2-0 and E2-4 groups, respectively in abdominal wounds. For ileal anastomoses 
these values were 32, 21 and 27%. Typical examples of ileal anastomoses (figure 6) 
illustrate the presence of less collagen (sirius-red positive) fibrils in the wound area 
from the E2-0 group (6B) than in the control (6A) and E2-4 (6C) groups. H&E staining 
suggested the absence of other obvious architectural differences (D-F).
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Figure 5. Wound hydroxyproline content. Data are expressed as hydroxyproline content per 5 mm tissue 
for ileal (A) and colonic (B) anastomoses and per mm tissue for fascia wounds (C) and represent mean 
and standard error of the mean (n=10). Black bars: control group: white bars: high dose everolimus. : 
p < 0.01 and (): 0.01 < p < 0.05 vs control group.
Figure 6. Histology of ileal anastomoses. Samples were colored with picrosirius red (A-C) or haematox-
ylin and eosin (D-F). Typical examples from control (A,D), E2-0 (B,E) and E2-4 (C,F) groups.
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Discussion
The use of immunosuppressants in solid organ transplantation is inevitable to 
prevent acute and chronic rejection of the transplanted organ. In the past decades 
new immunosuppressant drugs have been developed, resulting in a longer survival 
of the transplanted organs. Since the introduction of mTOR inhibitors concerns 
have been raised regarding their detrimental effects on wound repair.3-12 Such 
effects are not only relevant in the immediate post-transplantation period. Chronic 
use of some immunosuppressant drugs increases the risk of malignancies in solid 
organ transplantation.16-18 This might result in a rise in future operations in these 
patients with increased chances for wound complications such as leakage of bowel 
anastomoses or the development of incisional hernias. 
In previous experiments, repeated by others19, we demonstrated a dose dependent 
decrease of wound strength in rats which received everolimus from the day of 
operation onwards.13,14 The present data show that strength of healing tissue at 7 
days postoperatively can reach control values when the administration of everolimus 
is delayed by a few days. The number of days needed for this purpose may slightly 
differ for different tissues, although the same trend is observed in both intestine 
and fascia. 
The present study was carried out with a model that has been thoroughly validated 
for the evaluation of wound healing in the intestine and abdominal fascia.13,14,20,21 
The primary outcome parameter for anastomotic healing is wound strength, which 
can be measured as both bursting pressure and breaking strength, even in the 
same animal.15 If the tissue ruptures within the true anastomotic line, the former 
represents the ability of the wound to withstand intraluminal pressure and the latter 
its ability to resist forces applied longitudinally. Both type of forces are presumably 
at work during intestinal movement and therefore both parameters are very relevant, 
although they may behave independently.22 Any reduction in either of the two may 
be taken as a sign of impaired healing. We measured wound strength at 7 days 
after operation since in controls maximum increase of strength takes place in the 
proliferation phase, between days 3 and 7. Immediate post-operative administration 
of everolimus strongly affects wound strength at day 7 but not at day 3.13 
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The doses of 1 and 2 mg/kg everolimus have been chosen according to the 
dose range used in previous studies.13,14 Others have used similar doses to elicit 
immunosuppressive effects in rats.23-25 Daily oral doses of 1 or 2.5 mg/kg have been 
shown to result in trough levels approximating 6 and 8 ng/mL in rats.26,27 In patient 
studies trough levels are usually targeted at 3-15 ng/ml, although higher upper 
therapeutic concentrations are reported.28-30 The dosages used here are therefore 
of clinical relevance for the human situation.
Fascia healing is of particular importance in the prevention of hernias, a common 
complication reported in patients on mTOR inhibitors. Indeed, if everolimus is started 
immediately, fascia wound strength at day 7 is reduced by half. Restoration of fascial 
strength to values which are not significantly lower than controls is only observed 
if everolimus is withheld until the fourth postoperative day. 
In the intestine, taking together the outcome for all parameters for strength, 
including the bursting site where a shift into the wound area represents weaker 
anastomoses, the data show that an immediate postoperative start of everolimus 
leads to considerably weaker wounds at day 7. This effect can be prevented when 
the drug is witheld until day 2, for colon, or day 3, for ileum. Comparing this outcome 
to that for fascia might indicate that the time needed to avoid the induction of loss 
of strength could depend on the tissue(s) of interest. In this case, where animals 
undergo both a laparotomy and intestinal resection, uninterrupted fascial healing 
would require postponement of everolimus until the fourth day after operation. It 
is entirely conceivable that the delay needed in the administration of the drug will, 
to some extent, depend on the location of the wound(s) because the rate of repair 
varies between tissues.31
mTOR inhibitors are believed to affect proliferation of a multitude of cell types, 
among them fibroblasts.32 Indeed, cellular proliferation in the anastomotic area 
appears to be strongly reduced by everolimus.21 It stands to reason that the negative 
effects on wound strength are caused by interference with the proliferative 
phase of repair. Since collagen deposition is fundamental in restoring strength to 
healing wounds and fibroblasts are responsible for collagen synthesis, it is to be 
expected that, ultimately, compromised collagen metabolism underlies the reduced 
development of strength resulting from everolimus administration. Although wound 
histology shows no obvious abnormalities in overall architecture it is conceivable 
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that less collagen is present in the wound area. The current data, as those of previous 
experiments, 13,14 show that the wound hydroxyproline content at day 7 is reduced if 
drug administration is started early after operation and that a delay possibly results 
in higher levels. However, the sensitivity of this measurement is limited because in 
the samples used only a small percentage consists of true anastomotic tissue, but 
a larger part consists of surrounding, uninjured tissue, which may dilute any effect 
limited to the suture line. Still, the histological quantification of collagen fibers in the 
true wound area, although performed on a limited number of animals, supports the 
existence of such an effect . Also, it is not only the quantity, but also the quality, of 
collagen that determines wound strength. It has been suggested that administration 
of everolimus results in the deposition of collagen fibers in the anastomotic area 
whose alignment is less coordinated.21 
One should always keep in mind that this is an experimental study in rats and that 
extrapolation to the human situation should be made with caution. In other words: 
we do not know for sure that a delay of 2 days in humans will provide the same 
degree of protection against inferior wound healing.
Still, the data presented here emphasize that efforts to determine the best possible 
postoperative regimen of immunosuppressive drugs should include not only 
dosages but also timing. Preferably, mTOR inhibitors should be avoided in the first 
postoperative days after transplantation. Subsequently, the immunosuppressant 
regime should be adapted accordingly in any future peri-operative period in order 
to prevent complications such as anastomotic leakage or incisional hernia if further 
surgery, such as bowel resections or urinary tract operations, is needed. The ultimate 
goal should be to aim for a fine-tuning of all aspects of an immunosuppressive 
treatment, combining maximal rejection prevention with a minimum of surgical 
complication in solid organ recipients.
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Abstract 
Background.
Use of immunosuppressant drugs has been associated with complications in wound 
healing. The calcineurine inhibitor tacrolimus is thought to have a relatively low 
complication rate, but preclinical research has yielded contradictory data, prompting 
the current comprehensive study 
Methods.
Three groups of 33 male Wistar rats received a daily subcutaneous dose of 0,5, 2 
or 5 mg/kg tacrolimus. A control group received saline. On day 0 a resection of 
1 cm ileum and 1 cm colon was performed, and end-to-end anastomoses were 
constructed. Ten rats of each group were killed on day 3 and day 5 and the remaining 
animals on day 7. Both anastomoses and the wound in the abdominal wall were 
analyzed. Wound strength was the primary outcome parameter. 
Results.
Mean strength of the abdominal wall increased significantly over time in all groups 
(p<0.0001). Both the breaking strength and the bursting pressure of the ileum 
and colon anastomoses followed the same pattern. No differences were observed 
between control and experimental groups. In addition, no consistent differences 
were found between groups regarding wound hydroxyproline content and the 
activities of matrix metalloproteinase-2 and -9. 
Conclusion.
Tacrolimus does not affect early wound healing. 
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Introduction
Under different immunosuppressant regimes, wound healing disturbances are seen 
in 7-53% of kidney transplant recipients.1-4 The premise that all immunosuppressant 
drugs have a negative effect on wound healing is widely accepted, although 
often scientific proof is lacking or inadequate. Clinical studies almost invariably 
use a regime of several immunosuppressant drugs, making it difficult to attribute 
adverse effects to a single component.4,5 Thus, preclinical research is necessary to 
elucidate potential effects of individual drugs. This way we have demonstrated that 
everolimus, a m-TOR inhibitor, has a negative, dose- and time-dependent effect on 
experimental wounds in intestine and abdominal fascia.6,7
Today, the typical standard regime of immunosuppressant drugs in solid organ 
transplantation consists of a calcineurine inhibitor such as cyclosporin or tacrolimus, 
an antiproliferative agent (azathioprine or mycophenolate mofetil) and a steroid. 
In this regime, tacrolimus is the newer agent, and extensive research has been 
carried out to establish its benefit over cyclosporine.1,8-10 In contrast to most 
immunosuppressive drugs, tacrolimus, a macrolide derived from the fungus S 
tsukubaensis, is believed to have few or none adverse effects on wound healing. 
Still, as a calcineurin inhibitor, tacrolimus affects the first phase of T-cell activation. 
Because inflammatory T cells play a role in wound healing an effect of tacrolimus on 
wound healing is conceivable. Reported effects of tacrolimus in preclinical studies 
are contradictory, ranging from stimulation to inhibition of soft tissue repair.11-16 
A common drawback to these studies is the fact that, almost without exception, 
only one post-operative time point is evaluated, while wound healing is a complex 
process with different and overlapping phases.
The present comprehensive study has been performed to evaluate the effects of 
tacrolimus, used as a single drug in three different doses, and at multiple time points 
during healing of bowel anastomoses and abdominal fascia in rats. 
Material and Methods
One hundred-thirty-two male Wistar rats (body weight 240-260 g; Harlan, Horst, 
The Netherlands) were randomly divided into four groups of thirty-three animals. 
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The animals were housed two per cage and allowed to become accustomed to 
laboratory conditions for one week before the start of the experiment. All animals 
had free access to water and standard rodent chow (Ssniff Specialdiäten GmbH, 
Soest, Germany). Three groups received tacrolimus (Prograft®, Astellas, Killorglin, 
Ireland) subcutaneously in daily dosages of 0.5 (group T0.5), 2.0 (group T2) and 5.0 
(group T5) mg/kg/day from the day of operation until the end of the experiment. A 
control group received saline subcutaneously. 
Ethic Statement:
This study was carried out in strict accordance with the National Dutch Act on 
Experimental Animals. The protocol (number 080320) was approved by the Animal 
Ethics Review Committee of the Radboud University Nijmegen. (Permit number 
DEC-2008-114). In order to minimize suffering all surgery was performed under 
general anesthesia using isoflurane 3%, in a mixture of oxygen and nitrous 
oxide. Postoperative analgesia was performed with buprenorphine, 0.02 mg/
kg subcutaneously, twice daily for two days. The animals were killed by CO2/CO 
asphyxiation to reduce as much stress as possible. An individual animal welfare 
logbook was kept and reported back to the Animal Ethics Review Committee.
Surgical Procedure: 
On day 0, a midline laparotomy was performed followed by a resection of 1 cm ileum 
15 cm proximal to the ileocaecal junction and 1 cm colon 3 cm proximal to the rectal 
peritoneal reflection. End-to-end anastomoses were constructed with eight single-
layer, inverting, interrupted 8-0 ethilon (Ethicon) sutures. The abdominal fascia was 
closed with an absorbable, polygalactin 3-0 suture, the skin was closed with staples. 
A heating pad was used to maintain body temperature at 38°C. The intestines were 
covered with gauze pads soaked with 0.9 % NaCl to minimize desiccation. Fluid 
loss was compensated by administering 10 ml of 0.9 % subcutaneously direct 
postoperative. The animals were weighed daily and observed for signs of illness. 
All operative procedures were performed by the same investigator (MW). 
Wound strength: 
Ten rats per group were killed on day 3 and day 5 each, and the remaining animals 
were killed on day 7. In the latter group, EDTA whole blood was sampled for 
tacrolimus assay (see below). Relaparotomy was performed by excision of a part 
of the abdominal wall of approximately 4 by 4 cm, including the suture line of the 
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fascia. The anastomoses of ileum and colon were resected with adjacent bowel 
of approximately 4 cm in length and the suture line in the middle. The intestinal 
segments were carefully resected, including surrounding tissues and adhesions, and 
washed in saline. Bursting pressure and breaking strength were measured in the 
same segment as described previously.17 In the abdominal wall the breaking strength 
was measured in the same way; from each segment of the abdominal wall, two 
separate strips of 1 by 2 cm were collected, with the suture line in the middle, and 
the breaking strength was measured in both. After biomechanical analysis, segments 
were cleaned from adhering tissue and standard sized samples containing the suture 
line were frozen in liquid nitrogen and stored at -80°C until further processing.
Biochemical analysis and histology: 
After lyophilisation, tissue samples were weighed, pulverized, and lyophilized again. 
Both hydroxyproline content and gelatinase activity were measured in control, T2 
and T5 groups. The hydroxyproline content, as a measure of the collagen content, 
was measured by high-performance liquid chromatography after hydrolysis with 
6-N-hydrochloric acid and derivatization with dabsyl-chloride. 
Preparation of tissue extracts and procedures for gelatin zymography have been 
described previously.18 The protein concentration of the extracts was measured using 
the bicinchoninic acid reagent. The various gelatinase activities were quantitated 
on the basis of lysed area and expressed as arbitrary units. Comparison of values 
obtained on different gels was performed by using collagenase type I (from 
Clostridium histolyticum; Sigma Chemical) as an internal standard. The presence of 
true matrix metalloproteinase (MMP) activity was confirmed by adding 10 mmol/L 
EDTA or 1,10 phenanthrolene to the buffers used after electrophoresis. Tacrolimus 
in whole blood was assayed using a PRO-TracTM ELISA kit from DiaSorin (Stillwater, 
Minnesota, USA). Sections of anastomoses originating from separate animals in the 
groups sacrificed after 7 days that had not been subjected to strength measurements 
were washed in 0.9% NaCl, spread out, and fixed immediately in a 4% phosphate-
buffered formaldehyde solution. Subsequently, the samples were dehydrated and 
embedded in paraffin blocks. Sections of 4 mm in thickness were stained with 
hematoxylin and eosin (H&E).
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Statistical analysis: 
To analyze differences in body weight and MMP-activity a Kruskal Wallis followed by 
Dunn’s test was used. Data of breaking strength, bursting pressure and hydroxyproline 
content were analysed with ANOVA followed by Tukey-Kramer post test. 
Results
The mean trough level of tacrolimus, as measured in whole blood collected on day 
7 after operation, was 0.3 ± 0.2 (SD) ng/ml in the control group and 4.9 ± 2.4, 10.1 ± 
2.0 and 12.3 ± 5.6 ng/ml, respectively, in the T0.5, T2 and T5 groups.
Eight animals died prematurely or were taken out of the experiment because of poor 
health: one each in the control and T0.5 groups (ileus), two in the T2 group (unknown 
reasons and excessive weight loss, respectively) and four in the T5 group (two after 
excessive weight loss and two of unknown reasons). Diarrhea, observed at least once 
during the experiment, was found in 1/32 of the surviving rats in the control group 
and in 0/32, 2/31 and 7/29 (p=0.022) in the T0.5, T2 and T5 groups, respectively.
All animals experienced a transient weight loss of approximately 10-15% of their 
body weight. From day 4 onwards they regained weight, those in the control group 
approximating their pre-operative weight at day 7 (Figure 1). However, the weight 
gain in animals receiving tacrolimus was less than in the control group. The relative 
weight in all experimental groups at day 7 was significantly (p<0.05) lower than in 
the control group.
Wound strength
Individual values for anastomotic bursting pressures in the intestine are given in 
Figure 2. They increased with time from day 3 onwards and, at all time points, 
median values were comparable in all four groups. From day 5 the bursting site was 
increasingly frequent outside the true anastomotic area.(Table 1) An increase in the 
number of anastomoses bursting outside the suture line represents an increase in 
anastomotic strength. Altogether, this phenomenon occurred equally frequent in 
control and tacrolimus groups.
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Figure 1. Postoperative course of body weight. Points represent average relative body weight, in re-
lation to the weight prior to operation, for the control group (□) and the groups receiving tacrolimus: 
T0.5 ( ), T2 (∆) and T5 ( ). 
Figure 2. Anastomotic bursting pressure. Individual values and medians (horizontal lines) in ileum and 
colon. A,B,C = ileum 3,5 and 7 days postoperative. D,E,F = colon 3, 5 and 7 days postoperative. X-axis: 
study groups. Open symbols denote rupture outside the suture line and closed symbols rupture inside 
the suture line. 
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Table 1. Anastomotic bursting site. Numbers represent the frequency of the bursting site being without 
the actual suture line.
Wound breaking strength is depicted in Figure 3. After 3 days fascia strength was 
very low but increased rapidly thereafter. For all groups, the gain in fascia strength 
was very significant (comparison of values at 3, 5 and 7 days by ANOVA: p<0.0001) 
and similar. At no time there were significant differences between the four groups. 
For the intestinal anastomoses, the gain in strength between day 3 and day 5 was 
less explicit. Still, for all groups anastomotic strength increased significantly (p<0.05) 
with time, values at day 7 always being higher (Tukey-Kramer, p<0.05) than those at 
day 3. A significant difference between groups was only found for ileal anastomoses 
at day 7 where strength was higher in the T5 group than in the control group. 
Breaking always occurred within the suture line.
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Figure 3. Wound breaking strength. Data represent mean and SEM in the control groups (white bars) 
and the T0.5 (black & white bars), T2 (grey bars) and T5 (black bars) tacrolimus groups. A= ileum anas-
tomoses, B= colon anastomoses, C = fascia.
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Wound collagen content and gelatinase activity
Wound hydroxyproline, as a measure for collagen content is given in Figure 4. 
Generally speaking, it increased with time, values at day 7 almost invariably being 
significantly (p<0.05) higher than those at day 3. In ileum, there were no differences 
between controls and experimental groups. In colon, values in the T5 group were 
lower than in the T2 group but equivalent to those in controls. In fascia, the 
hydroxyproline content was highest in the T5 groups.
The results of the zymographic measurements of gelatinase activity, in ileal and 
colonic tissue at day 3 and 7, are summarized in figure 5. The activities of proMMP-
9 and proMMP-2 were similar in control and tacrolimus groups. Although MMP-9 
activities were low and varied considerably between animals, they appeared higher 
in the tacrolimus groups, especially in ileum. For MMP-2, differences were seen in 
colon where tacrolimus apparently lowered activity at day 3 while increasing it 
after 7 days. 
Histology
A comprehensive examination of sections obtained from controls and the T0.5 
and T2 groups failed to reveal any obvious architectural differences at day 7. 
Semiquantitative analysis also failed to indicate any differences between control and 
the tacrolimus groups with respect to histologic parameters such as mucosal repair, 
epithelial damage, wound area surface, degree of necrosis, and cellular infiltration.
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Figure 4. Wound hydroxyproline content. Data are expressed as hydroxyproline content per 5 mm tissue 
length and represent mean and SEM for the controls (white bars) and the T2 (grey bars) and T5 (black 
bars) tacrolimus groups. A= ileum, B= colon, C = fascia. * : p<0.05 vs T2 group; #: p<0.05 vs control group.
6
116
Chapter 6
Figure 5. MMP activity in intestinal anastomoses. Columns represent mean values + SEM for controls 
(white bars) and the T2 (grey bars) and T5 (black bars) tacrolimus groups. Data represent total activities, 
in arbitrary units, per 5-mm segment for proMMP-9 (A), MMP-9 (B), proMMP-2 (C), and MMP-2 (D). *: 
p<0.05 vs control group.
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Discussion
Although clinical studies of the effects on wound healing of single immunosuppressive 
drugs are lacking, wound complications after solid organ transplantation are often 
attributed to these drugs. Regimes including rapamycin derivates have been shown 
to be associated with more wound complications than those with calcineurin 
inhibitors. Our earlier experimental studies demonstrated a profound negative 
effect of everolimus on wound healing in the rat.6,7 The present data clearly show 
that tacrolimus has no such effect and that surgical wounds demonstrate normal 
repair in the critical first week after operation, even during administration of doses 
leading to high trough levels of the drug. There is also no evidence for improvement 
of wound healing with tacrolimus.
Calcineurin inhibitors are notoriously known for their chronic toxicity and consequent 
chance of graft loss. Although cyclosporine and tacrolimus essentially inhibit the 
action of calcineurin in the same way, their side effects differ slightly. Tacrolimus is 
superior to cyclosporine in preventing acute rejection and improving graft survival 
which has resulted in an enormous increase in use of the agent since introduction 
in 1989.10 Tacrolimus has a greater effect on impairing the expression of alloantigen 
stimulated T-lymfocytes than does cyclosporine 19 but supposedly a less significant 
effect on wound healing. Clinically, it is always used together with other drugs, 
therefore, its safety in terms of interference with wound repair must be assessed 
in a preclinical model.
Preclinical data on the effects of tacrolimus on wound healing are few and 
contradictory. Doses of 2 mg/kg/day reportedly inhibit skin healing, but not colonic 
or ileal anastomotic healing.11,12,14,15 Kiyama et al. even found that low doses (0.01 
– 1 mg/kg/day) increased wound strength in the colon but not in the ileum.13 In all 
these experimental studies wound repair was analyzed at one time point only. Raptis 
et al. also used a low tacrolimus dose of 0.1 mg/kg/day and reported evidence of 
enhanced rodent colonic anastomotic healing, measured as bursting pressure at 4 
and 8 days postoperatively.16
In order to obtain data which would allow a comprehensive analysis of the possible 
effects of tacrolimus on soft tissue repair we analyzed wounds in intestine and 
abdominal fascia. Tacrolimus was administered in three doses which, dose-
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dependently, led to trough levels ranging from 5 to 12 ng/ml. These levels are in 
the range often reported in clinical studies.20 Finally, the study included three time 
points, covering the inflammatory and early proliferative phases of the healing 
sequence. The first week after operation is particularly important because wound 
strength remains low during the first few days and increases from day 3 onwards. 
Any interference in this period will enhance chances on wound dehiscence.
The results presented here are unambiguous. Tacrolimus, in three different clinically 
relevant dosages, does not interfere with and does not promote wound strength, 
which is the primary functional outcome parameter. This result holds for wounds 
in both small and large bowel and in the abdominal fascia at any of the three 
time points measured. For the bowel anastomoses, we measured two independent 
parameters for strength, the bursting pressure and the breaking strength. The 
bursting pressure, which represents the ability to withstand intraluminal pressure, 
only reflects wound strength if the bursting site is within the suture line which will 
not always be the case after day 3. Therefore, it is very relevant to collect additional 
data for the breaking strength, which reflects wound strength over the entire period 
analysed here. Interestingly, undisturbed healing proceeded despite the fact that the 
rats in the experimental groups were clearly in a more catabolic state than those 
in the control group (figure 1). 
The introduction of new immunosuppressant agents has increased graft 
survival. However, at the same time, long term complications not related to graft 
function, become increasingly important, much of them due to development of 
cardiovascular disease or malignancies, related to the use of immunosuppressant 
drugs. The proportion of deaths attributed to malignancy in the first decade after 
transplantation is as high as 26 % and rising.21 Presumably, this phenomenon will 
result in a rise in future operations not related to the transplanted organ. Surgery 
needs to be executed under immunosuppressant therapy, possibly with increased 
chances of wound complications such as bowel leakage or incisional hernia. The 
present data emphasize the fact that tacrolimus, contrary to other drugs used for 
immunosuppression, does not have a negative effect on wound healing. This may 
be of clinical consequence in the direct post-transplant phase, as well as in patients 
on immunosuppressant therapy that have to undergo surgical procedures for other 
reasons. Such knowledge, obtained from preclinical studies as the present one, is 
119
Tacrolimus does not affect early wound healing in a rodent model of bowel anastomoses and
very relevant for determining an optimal immunosuppressant regime in terms of 
composition, timing and dosage.
Conclusion
Tacrolimus, as a single drug, does not influence the repair sequence in soft tissues 
during the first week after operation. 
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Abstract
Background.
Immunosuppressant agents are inevitable for solid organ recipients, but may have 
a negative effect on wound healing that is difficult to measure because of clinical 
use of a poly-drug regime. The evidence on mycophenolate mofetil (MMF) is scarce 
and contradictory. This study aims to investigate the effect of MMF administration 
on wound healing.
Methods.
Ninety-six Male Wistar rats divided into four groups underwent anastomotic 
construction in ileum and colon at day 0. Three groups received daily oral doses of 
20 mg/kg or 40 mg/kg MMF or saline (control group) from day 0 until the end of 
the experiment. Half of each group was analyzed after 3 days and half after 7 days. 
Another group started the medication three days after the laparotomy and was 
analyzed after 7 days, half of this group received 20 mg/kg and half 40 mg/kg MMF. 
Wound strength in anastomoses and in the abdominal wall was measured using 
bursting pressure, breaking strength and histology. Through levels were measured. 
Results. 
Animals in the experimental groups showed no more gastrointestinal complications 
that animals in the control group, but animals in the high-dose group showed 
significantly more weight loss than the control animals. This difference disappeared 
at 7 days. Significant differences in wound strength were only seen in ileum 
tissue after 3 days. Surprisingly, the ileum showed a stronger anastomose in the 
experimental groups. Bursting pressure was higher in the high dose MMF group 
compared to the control group, breaking strength was higher in the low dose MMF 
group compared to the control group. Histology showed poorer bridging of the 
submucosal layer and more polymorfonuclear cell infiltration in the ileum specimens 
of the control group.
Conclusions.
As a single agent in a preclinical wound healing model in the rat, MMF has no 
negative effects on wound healing.
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Introduction
Due to a steady rise in numbers of solid organ transplantation, as well as a marked 
increase in efficacy and safety of the immunosuppressant treatment scheme, 
recipients of solid organs rise in number and age. In fact, the number of people 
living with a functioning kidney transplant in the United States doubled between 
1995 and 2004 and almost doubled again by the end of the year 2012, even though 
numbers of kidney transplantations per year have not increased since 2006.1,2 Side 
effect of this development is the fact that surgeons are increasingly confronted with 
transplant patients in need of an operation, either related to their transplanted organ 
or to other diseases, such as aneurysms or malignancies.3-6 It is well established that 
solid organ recipients are at a higher risk of developing malignancies compared 
to the general population.5-7 Immunosuppressant therapy is presently inevitable 
in solid organ recipients, and most drugs in the poly-drug regimen of medication 
have been associated with wound healing complications. A well-know regimen of 
immunosuppressant drugs in solid organ transplantation consists of a calcineurine 
inhibitor such as tacrolimus or cyclosporine (CsA), an antiproliferative agent such 
as mycophenolate mofetil (MMF) or azathioprine (AZA) and a steroid. With different 
immunosuppressant regimens wound complications of the initial organ transplant 
operation have been reported up to 52%.8-12
Many clinical studies have been carried out in order to identify immunosuppressant 
drugs with a high complication rate.8-12 However, it is difficult to entangle the effects 
on wound healing in a clinical study, where a poly-drug study regimen is used. 
Furthermore, most clinical studies report adverse events, without consistent focus on 
wound healing complications. Despite all this, cumulating evidence has led to some 
modifications in clinical practice. In recent years loading doses of mTor inhibitors, 
such as sirolimus and everolimus are avoided if possible in the light of the wound 
healing complications. An increasing awareness of the risk of wound complications 
of mTOR inhibitors has limited its use in the immediate postoperative phase. In this 
light, it is important to know the effect on wound healing of the other agents that 
are frequently used in the direct postoperative phase.
Mycophenolate mofetil (MMF) has been used as immunosuppressant for more than a 
decade. It is also frequently used to treat acute rejection after transplantation. MMF 
efficacy is attributed to its inhibitory activity on lymphocyte functions. After oral 
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administration, MMF is rapidly absorbed and then converted to mycophenolic acid 
(MPA) which is the active immunosuppressant. MPA inhibits the activity of inosine 
monophosphate dehydrogenase, a rate-limiting enzyme for the novo synthesis of 
guanosine nucleotides. By depleting the intracellular concentration of guanosine 
nucleotides, MPA acts as a potent inhibitor of lymphocyte proliferation. 
Roos et al have demonstrated that MMF inhibits collagen gene expression and 
fibroblast migration.13 Preclinical studies with this drug have been carried out in 
vitro13,14 as well as in pulpal tissue healing in dogs.15 A well-known and validated pre-
clinical model for wound healing is a bowel anastomose model in rats. Earlier studies 
have measured a negative effect of MMF on the healing of bowel anastomoses.16,17 
However, an intractable difference in the regime of these studies with the clinical 
situation is the fact that in these studies MMF is started at days 3 and 7 prior to the 
operation, while in humans, immunosuppressant drugs start immediately after the 
transplantation operation. It is clinical relevant to find out if a negative effect on 
wound healing of MMF exists when starting MMF at the day of operation. In case 
a negative effect of MMF on wound strength is found, it will be interesting to find 
out if any persistence of the effect is measured when delaying MMF for 3 days, as 
we have proved to be true for Everolimus, in the same bowel anastomosis model.18
Materials and Methods
Ninety-six male Wistar rats (body weight 240-260 g; Harlan, Horst, the Netherlands) 
were randomly divided into four groups of twenty-four animals. The animals were 
housed two per cage and allowed to become accustomed to laboratory conditions 
for one week before the start of the experiment. All animals had free access to 
water and standard rodent chow (Ssniff Specialdiäten GmbH, Soest, Germany). Two 
groups (group MMF20-0 and MMF 40-0) received MMF (Cellcept®, Roche, Woerden, 
the Netherlands) orally in daily dosages of 20 mg/kg and 40 mg/kg from the day of 
operation to the end of the experiment. Another group started the study medication 
on day 3 instead of day 0. Half of these animals received 20 mg/kg, and half 40 mg/
kg MMF daily until the end of the experiment (groups MMF20-3 and MMF 40-3.) A 
control group of 24 animals received saline orally from the day of operation until 
the end of the experiment. The study was approved by the Animal Ethics Review 
Committee of the Radboud University Nijmegen.
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Surgical Procedure
On day 0, a laparotomy was performed under general anesthesia using isoflurane 
3%, in a mixture of oxygen and nitrous oxide. A midline laparotomy was followed 
by a resection of 1 cm ileum 15 cm proximal to the ileocaecal junction and 1 cm 
colon 3 cm proximal to the rectal peritoneal reflection. End-to-end anastomoses 
were constructed with eight single-layer, inverting, interrupted 8-0 ethilon (Ethicon) 
sutures. The abdominal fascia was closed with an absorbable, polygalactin 3-0 
suture, the skin was closed with staples. A heating pad was used to maintain body 
temperature at 38°C. The intestines were covered with gauze pads soaked with 0.9 
% NaCl to minimize desiccation. Fluid loss was compensated by administering 10 
ml of 0.9 % subcutaneously directly postoperative. Postoperative analgesia was 
performed with buprenorphine, 0.02 mg/kg subcutaneously, twice daily for two 
days. The animals were weighed daily and observed for signs of illness. All operative 
procedures were performed by the same investigator (MW).
Wound strength
Of the control group and of the MMF-20-0 and MMF-40-0 groups, twelve rats were 
killed on day 3 and twelve on day 7 postoperatively. Of the groups with delayed 
medication, all rats were killed on day 7 postoperatively. The animals were killed 
by CO/CO2 asphyxiation. Relaparotomy was performed by excision of a part of 
the abdominal wall of approximately 4 by 4 cm, including the suture line of the 
fascia. The anastomoses of ileum and colon were resected with adjacent bowel 
of approximately 4 cm in length and the suture line in the middle. The intestinal 
segments were carefully resected, including surrounding tissues and adhesions, and 
washed in saline. Bursting pressure and breaking strength were measured in the 
same segment as described previously.19 In the abdominal wall breaking strength 
was measured in the same way; from each segment of the abdominal wall, two 
separate strips of 1 by 2 cm were collected, with the suture line in the middle, 
and breaking strength was measured in both. In each group 2 rats were used for 
hematoxylin and eosin staining and histologic description. After biomechanical 
analysis, segments were cleaned from adhering tissue and standard sized samples 
containing the suture line were frozen in liquid nitrogen and stored at -800C until 
further processing.
7
130
Chapter 7
Histology
Animals to be used for histological evaluation of the wound were killed as 
described previously. Intestinal samples of approximately 1cm length containing the 
anastomosis in the middle were carefully resected en bloc, opened at the mesenteric 
side, and washed gently in 0.9% NaCl. They were spread out and immobilized and the 
samples were immediately fixed in 4%  phosphate-buffered formaldehyde, pH 7.3. 
Each anastomosis was divided into two or three longitudinal strips. Specimens were 
dehydrated and embedded in paraffin. Sections of 4 mm in thickness were stained 
with hematoxylin and eosin. Sections were analyzed and assessed by histological 
parameters for anastomotic repair as described before.20
Mycophenolate mofetil:
Of 4 rats in each of the following groups: control, MMF 20-0 and MMF 40-0 blood 
was sampled to determine through levels of MPA. Since we did not need to sample 
blood for other reasons we chose to sample blood by direct heart puncture when 
the animals were killed, for humane reasons. MPA levels were determined by high 
performance liquid chromatography.
Statistical ananlysis
Through levels are expressed as mean ± standard deviation. To analyze differences 
in body weight a one way anova was used. Differences of bursting inside or outside 
the suture line of the anastomosis were analyzed with the Fisher’s exact test. Data 
of breaking strength and bursting pressure were analyzed with the Wilcoxon Mann 
Whitney test. A p value of <0,05 was considered a significant difference.
Results
MPA trough levels
Of all 4 animals of the control group the MPA trough level was under the limit of 0.4 
mg/l. The mean MPA trough level in the MMF20-1 group was 0.5 mg/l ± 0.1, mean 
MMF trough level in the MMF40-1 group was 0.8mg/l, ± 0.4.
Weight
From the day of the operation, all the animals lost weight until the third or fourth day 
postoperative (Figure 1). The largest weight loss was seen in the group of high-dose 
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MMF (MMF40): on day 4 the mean weight of the animals wa 87.6% from starting point. 
On day 4,5 and 6 the weight in the group MMF 40 was significantly lower compared 
to the control group. In each group of high dose MMF (MMF 40-0 and MMF 40-3) one 
animal died for unknown reason. Autopsy in both animals revealed distended small 
bowel, which may be related to either the operation, or the medication. These animals 
did not suffer from gastro-intestinal signs such as diarrhea. During relaparotomy at 
the end of the experiment, two other rats from the MMF 40-0 group, both operated 
on day 3, showed signs of ileus, with distended small bowel. 
Figure 1. Postoperative course of body weight. Points represent average relative body weight, in relation 
to the weight prior to operation, for the control group (+) and the groups receiving MMF 20 (x), MMF 
40 (●), MMF 20 with delay (-) and MMF 40 with delay (∆). 
Wound strength
Individual values for bursting pressure of ileum and colon anastomoses and their 
bursting sites (within or outside the anastomoses) are given in figure 2. Compared 
to the control group, the anastomoses of the ileum were stronger in the MMF-
treated animals. This was significantly so in the MMF 40 group (p=0.005) after three 
days. For colonic tissue this was not the case. At seven days no difference could be 
noted for any of the groups. The number of burst sites outside the anastomoses is 
again shown in figure 3. We only show here the percentages after 7 days, when in 
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many animals the anastomoses has grown stronger than the surrounding tissue. 
The number of cases where the bursting takes place outside the anastomose is not 
different among the groups.
Figure 2. Anastomotic bursting pressure. Individual values and medians (horizontal lines) in ileum and 
colon. A = ileum control group 3 days postoperative versus MMF 20 and 40, B= colon control group 3 
days postoperative versus MMF 20 and 40, C = ileum control group 7 days postoperative versus MMF 
20 and 40 7 days postoperative and at 7 days but after a delay of 3 days, D= colon control group 7 days 
postoperative versus MMF 20 and 40 7 days postoperative and at 7days but after a delay of 3 days. 
X-axis: study groups. Open symbols denote rupture outside the suture line and closed symbols rupture 
inside the suture line. Significant P-values are marked with an asterisk.
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Figure 3. Number of burst sites outside the anastomosis. Data represent the frequency (percentages) 
of the bursting site outside and inside the actual suture line on day 7. Light gray represents bursting 
at the anastomose site in ileum, dark gray represents bursting outside the ileum anastomose. White 
represents bursting at the anastomose in colon and black represents bursting outside colon anasto-
mose, all measured at day 7. 
Breaking strength is shown in figure 4. Here, the ileum anastomoses of rats of 
the MMF 20 and of the MMF 40 group are significantly stronger than those of the 
control group (p=respectively 0.014 and 0.041). After 7 days no significant difference 
is measured. (p= respectively 0.072, 0.4, 0.2 and 0.12 for control versus groups 
MMF20-0, 40-0, 20-3-7 and 40-3-7) In colon tissue no difference can be measured 
between the control group and the experimental groups. (p= 0.57 and 0.33 at three 
days and 0.42, 0.94, 0.65 and 0.87 at 7 days). In abdominal wall tissue a decrease 
of strength is measured after 7 days in the high dose experimental group that was 
treated from day 0 (MMF40-0), the p value was 0.022. The low dose group in this 
experiment just failed to show a significant difference but showed the same trend 
(p=0.05). The negative effect disappeared when the medication was delayed for 
three day. P values at seven days were respectively 0.41, 0.36, 0.37 and 0.20 for 
groups MMF20-0, MMF 20-3-7, MMF 40-3-7 and MMF 40-1-3.
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Figure 4. Wound breaking strength. Data represent median and range in all groups. A, Ileum; B, Colon; 
C, abdominal wall. P values that are significant are marked with an asterix.
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Histology
No obvious architectural differences were seen between de different groups 
of the colon tissue or fascia tissue. However, in the ileum the accumulation of 
polymorfonuclear cells, macrophages and lymphocytes was more profound in the 
control rats than in the MMF20 or 40 rats, indicating less progress in healing of 
the anastomose. Even more striking was the fact that bridging of the mucosa and 
submucosal layer seemed to be less advanced in the control rats. (Fig 5)
Figure 5. Histology example of hematoxylin-and-eosin stained specimens. A; ileum anastomose in 
control rat at 7 days, B; ileum anastomose in 40-0 rat at 7 days. Arrows indicate suture material.
Discussion
The introduction of new immunosuppressive agents in the last decades has 
significantly improved outcome of solid organ transplantation but this improvement is 
accompanied with new adverse effects such as nephrotoxicity, lymphoceles or wound 
healing disturbances. Wound healing is a very complex process that is potentially 
influenced by all immunosuppressive agents, although this is difficult to assess 
in clinical studies, where patients receive a combination of immunosuppressant 
drugs. The problem with most clinical studies is that wound healing is not a primary 
endpoint but part of a standard adverse event listing that might be vulnerable 
to reporting bias. Compared to the vast amount of studies concerning transplant 
survival few studies or reviews have focused on wound healing. In 2012 Nashan 
reviewed the literature of immunosuppressant agents and wound healing.21 Herein 
MMF does not seem to have a clear benefit over mTOR inhibitors, although the 
7
136
Chapter 7
combination of MMF with mTOR inhibitors may have an additive negative effect on 
wound healing, as concluded from the study of Pengel et al.22 
Very few preclinical studies have been carried out in the past to determine the effect 
of MMF on wound healing.13,16,17,21 Zeeh et al were the first to show a negative effect 
on healing of bowel anastomoses in rats on systemic MMF, started three days prior 
to surgery.16 However, in this study, MMF was administered intraperitoneally, which 
may have had a direct effect on the colonic anastomoses, and not mimic the orally 
administration of human organ recipients.
MMF is a “prodrug” which is metabolized in the active mycofenolic acid (MPA), a 
specific inhibitor of inosine monofosphate dehydrogenase. This is a key enzyme for 
de novo synthesis of guanosine nucleotides, essential for DNA and RNA synthesis 
and necessary for maximum lymphocyte proliferation. The immune suppressant 
action is therefore based on a decrease of proliferation of T and B lymphocytes 
and monocytes. There is also evidence that MMF inhibits the action of fibroblasts 
and other cells that are not part of the immune system.13 A negative effect of MMF 
on wound healing is therefore plausible, even when started postoperatively, as is 
the case in new transplant recipients. The experiment presented here, is carried 
out to measure the effects of MMF on the healing of bowel anastomoses and 
abdominal wall after laparotomy. In the first postoperative week wound strength is 
relatively low and chances of complications are high. To guarantee that no effect 
of MMF is missed, two time-points of measurement were incorporated: three days 
postoperative, which represents the end of the inflammatory phase, when wound 
strength is known to be at the weakest point and seven days after operation, which 
is during the proliferation phase, when the wound strength is increasing rapidly. 
MMF is administered orally, in two different dosages: 20 mg/kg and 40 mg/kg 
bodyweight. These dosages have proven to have a sufficient immunosuppressant 
action in rats and lead to clinically relevant MPA trough levels.23 Two rats in the high 
dose group died prematurely of unknown reason but did have distended small bowel. 
This might be related to the study medication because the therapeutic window of 
MMF is narrow. In some preclinical studies dosages of 40-60 mg/kg were not well 
tolerated by rats.23,24 
The weight loss at 4,5 and 6 days postoperative was significantly greater for the 
animals treated with the highest dose of MMF (MMF-40). This observation is also 
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made by Schuurman et al, where they compared the MMF-CSA combination with 
CSA only.24 MMF is known for dose-dependent gastrointestinal side effects such 
as diarrhea,26 but although side effects were recorded, no more cases of diarrhea 
were seen in the experimental groups compared to the control group. At day 7 the 
difference between the MMF 40 group and the control group disappeared, thus 
showing an adequate recuperation of the rats in the MMF 40 group. 
The results presented here show a positive effect of MMF on the healing of ileum 
anastomoses, no effect on the healing of colon anastomoses and a negative effect 
when started at day 0 on the healing of the abdominal wall. Bursting pressure 
after three days in ileum anastomoses of the MMF treated animals is significantly 
higher than in the control group. In the measurement of breaking strength in 
ileum after three days we a similar pattern. In the colon no significant difference 
in bursting pressure or breaking strength is noted between the control group and 
the experimental groups at three or at seven days. In the measurement of bursting 
pressure, the site of bursting represents indicates the strength of the anastomoses.
After day three, when the wound has gained a considerable amount of strength, 
the bursting site will often be outside the anastomosis. This means that the 
anastomosis has grown stronger than the adjacent tissue, and the measurement 
itself does not represent wound strength anymore. However, the rising proportion 
of bursting sites outside the anastomosis does indicate an increase in strength. 
This increase in strength is seen clearly in all groups comparing day three to day 
seven. Although a trend is seen towards a decrease in proportion of bursting sites 
outside the anastomoses, particularly in the high dose groups (MMF40) and in the 
delayed low dose group (MMF20-3), these differences were not statistically different. 
The only negative effect of MMF is seen in the abdominal wall tissue, where a 
significant decrease of breaking strength is seen in the highest dose group, when 
the medication was started on day 0. The negative effect disappeared when the 
medication was delayed for three days. The abdominal wall model might therefore 
be a more sensitive model to wound healing than the bowel anastomose model. 
The data presented here show a divers effect of MMF on its own, dependent on 
the tissue that the effect is measured in. We have found no published data in the 
literature on a different effect of MMF according to tissue, as preclinical effects are 
usually measured on one tissue type only. Limitations of this study are the fact that 
we do not know if the dosages used are directly transferable to the human situation. 
Although pharmacokinetics in humans and rats are similar, the dosage of 40mg/kg 
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may have been too high. Furthermore, as in all animal studies, we do not know if 
these findings are directly transferable to humans. 
Conclusion
As a single agent in a preclinical wound healing model in the rat, MMF has a negative 
effect on healing of the abdominal wall, which could possibly be prevented by 
delaying the medication for three days. No negative effect was found on the wound 
healing of bowel anastomoses.
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History
Awareness of wound healing changed while the use of immune-suppressant agents 
was rising in the fifties. In 1949 and 1950 different research teams investigated the 
effect on wound healing of cortisone or ACTH in a preclinical setting.1-4 Except for 
two studies the reports were based on the histological appearance of the wounds. 
Howes at all studied the tensile strength of wounds of the stomach, muscle and skin 
in the rat at six days, finding a significant decrease in tensile strength.1 Alrich et all 
showed a delay in wound healing in cortisone treated rats that lasted throughout 
the experiment of 12 days.5 After this first year of 1950 with a lot of interest in 
wound healing, Sandberg discovered in 1964 that the effect on wound healing of 
cortisone occurred only when the drug was given in moderate or large amounts 
within the first 2 or 3 days after injury.6 Ehrlich et al found a 28% decrease in wound 
strength measured by tensile strength of dorsal wounds in rats that used cortisone. 
A concomitant use of vitamine A prevented cortisone to affect the wounds.7 In 
the early eighties cyclosporine A was the new immunosuppressive agent for 
transplantation surgery, and, as well as cortisone, this was also tested in preclinical 
research. Nemlander et all concluded that intra-peritoneal cyclosporine A did not 
inhibit the inflammatory reaction of granulation tissue formation by measurement 
of wound fluid.8 However, Fishel et all concluded that orally given cyclosporine A did 
impair wound healing by measurement of wound strenght.9 Very few investigations 
for azathioprine have been carried out and only in combination with prednisone.10-12 
The introduction of newer immunosuppressant agents raised new concern about 
wound healing and prompted research in pre-clinical setting.
mTOR inhibitors
Preclinical studies have been carried out by different groups with different intentions. 
From the end of the last century on, studies have been carried out to describe the 
effects of any rapamycin derivative on wound healing. A diversity of tissues has 
been tested and analysis of repair is mostly restricted to one time point only. Dutley 
and coworkers have reported an impaired breaking strength of airway anastomoses 
at postoperative day 14 in pigs that received 1.25 mg/kg per day of everolimus.13 
Two other studies purport to demonstrate reduced strength of ureter and bile duct 
anastomoses on the fifth day after surgery in pigs treated with rapamycin, but the 
small size of the groups investigated precludes significance of any of the effects.14,15 
Gaber et al investigated the tensile strength of median laparotomy wounds in rats 
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that were treated with low dose or high dose sirolimus, with or without concomitant 
steroid use. Their paper dates from 2006.16 They measured at different time points 
(5,10 and 15 days postoperatively) and found a gradual increase in tensile strength of 
the wounds. High dosages of sirolimus caused reduction in wound strength until day 
ten and concomitant use of steroids prolonged wound recovery with a very profound 
effect of >50% reduction of tensile strength which lasted longer than the duration of 
their experiment. Then van der Vliet et all from our own group showed in 2006 that 
healing of colon tissue in anastomoses in rats was impaired by a significant decrease 
of hydroxyproline-content after treatment with everolimus.17 This demonstrated 
for the first time, that the use of mTOR inhibitors results in a decrease of wound 
strength by reducing protein synthesis. Schäffer et all tried to unravel the effect 
in 2007 by measuring not only wound strength of dorsal skin incisions in rats but 
also Vascular Endothelian Growth Factor (VEGF) and nitrite and nitrate (both stable 
end-products of nitric oxide) in wound fluid.18 Nitrate/nitrite levels were lower in 
the wound fluid of the higher dosage sirolimus treated rats (2 and 5 mg/kg), and 
were also diminished in the immunohistochemical staining of sections of the wound 
at 10 days. VEGF was only diminished in the skin wound sections. They concluded 
that wound cells of sirolimus treated rats synthesize less nitric oxide and VEGF 
and therefore show impaired wound healing. Ekici et all, in 2007, compared the 
inflammatory cells and myofibroblast proliferation in cells of abdominal wall and 
bladder that had been opened and closed 7 days before.19 The rats were treated 
with 3 mg Rapamycin per day. Eosinophil and neutrophil leucocyte infiltration 
were significantly higher in the control rats, and myofibroblast proliferation was 
significantly reduced in the treated rats. They also measured the mean percentage 
of cells expressing VEGF which was significantly lower in rapamycine treated rats. 
Hydroxyproline measurements did not differ significantly between the placebo and 
treated group. In 2008 Wagner and coworkers concluded that sirolimus does not 
impair the healing of bowel anastomoses, in seeming contradiction to data reported 
earlier by us for everolimus.20 However, these authors based their conclusion on an 
experiment with colon anastomoses that lasted only 4 days. Proliferation inhibitors 
such as sirolimus and everolimus are logically thought to affect the proliferative 
phase of wound healing, which starts around the third postoperative day. It is 
therefore very likely that their effects only become apparent somewhat later. In 
2009 our group investigated the persistence of the effect of everolimus on wound 
healing, again in rat colon and ileum anastomoses, adding also measurements in 
abdominal fascia. We found that not only after 7 days, as in the first experiment, but 
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also on day 14 and 28 breaking strength of ileum, colon, and fascia was consistently 
and significantly reduced in the experimental groups.21 In 2011 our group showed 
that a short delay of everolimus had a very positive effect on wound strength.22 In 
ileum and colon, strength was the same as in the control group when everolimus 
was delayed for 3, respectively 2 days. In fascia healing, this was the case only 
when everolimus was withheld for 4 days. In 2011 the findings of van der Vliet 
from 2006 were confirmed by Küper et all in an experiment very much like that 
of van der Vliet et all.23 They also showed that the inflammatory reaction in the 
anastomosis was increased by means of increased myeloperoxidase (MPO)-positive 
cells and increased activity of the matrix-metalloproteinases 2 and 9 (MMP2/9) 
indicating a delayed phase of proliferation. Very recently, Küper et all found that 
the combination of human growth hormone and everolimus resulted in an improved 
wound healing compared to using everolimus alone.24 The measurement of bursting 
pressure was significantly lowered by everolimus and the concomitant use of human 
growth hormone showed considerably (but not significant) higher burst pressures. 
Hydroxyproline measurements were significantly higher in rats using concomitant 
human growth hormone and the hematoxylin and eosin stained histology in these 
rats revealed significantly more granulation tissue.
We can conclude that the use of mTOR inhibitors results in a decrease of wound 
strength by reducing protein synthesis, and the cells in the healing wound produce 
less VEGF than those of animals not treated with mTOR inhibitors. The impaired 
wound healing persists for at least 28 days and can be easily be prevented by a short 
delay of the administration postoperatively.
Tacrolimus
Preclinical data on the effects of tacrolimus on wound healing are few and 
contradictory. In 1998 Schäffer et all showed for the first time that tacrolimus impairs 
wound healing and that this is reflected by diminished wound nitric oxide synthesis.25 
They made dorsal skin incisions in rats that received 0.5, 1.0 or 2.0 mg tacrolimus/
kg intraperitoneally. Their experiment was the same as their experiment described 
above for everolimus.18 In short: they measured protein concentrations and nitrite and 
nitrate levels in wound fluid. The administration of 2.0 mg/kg tacrolimus diminished 
hydroxyproline content, mechanical strength and nitrite and nitrate concentrations, 
but not protein concentrations in wound fluid. In 2005 they carried out a different 
experiment: they administered intraperitoneal tacrolimus 1.0 or 2.0 mg/kg in rats 
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that underwent colonic anastomoses and 2.0 or 5.0 tacrolimus/kg subcutaneously 
in rats that were subjected to dorsal incisions.26 The experiment was ended after 
5 days. They found an impaired wound healing in the intra-peritoneal treated rats, 
but not in the subcutaneously treated rats. The intra-peritoneal treated rats showed 
a decrease in Transforming Growth Factor β (TGFβ, which is known to promote 
healing) and an increase in Transforming Growth Factor α (TGFα), and Interferon 
gamma (IFNγ) concentrations which are both known to inhibit healing.26 In 1999 Kita 
et all carried out an experiment very much like the experiment we did later, but they 
administered tacrolimus (2.0 mg/kg) intraperitoneally instead of orally. After 7 days, 
they found a significant decrease in anastomotic bursting pressure of the colon, but 
not of the anastomosed ileum of the rats.27 Completely contradictory to Kita, Kiyama 
et all even found that low doses (0.01 – 1 mg/kg/day) increased wound strength in 
the colon but not in the ileum.28 The finding was repeated by Raptis et all in 2012, 
who saw a promotion of wound healing in rat colon anastomoses.29 Tacrolimus was 
given subcutaneously (0.1mg/kg) and assessed at day 4 and 8 by measuring bursting 
pressure, by assessing histopathological specimens for inflammatory cell infiltration 
and by assessment of hydroxyproline concentration and collagenase I concentration. 
The bursting pressure for the tacrolimus treated group was higher at 4 days and 
at 8 days postoperatively, and the percentage of leakage at the anastomotic site 
was lower in the tacrolimus group. Inflammatory cell infiltration was lower in the 
tacrolimus groups. Hydroxyproline tissue concentration was significantly increased 
in the tacrolimus groups and collagenase I concentration was lower in these groups. 
In this experiment, a clear promotion of wound healing was noted, although only 
one concentration of tacrolimus was tested. In 2003 Wasserberg et all tested groups 
of rats that either received an allogenic ileum transplantation or a syngeneic ileum 
transplantation with or without the use tacrolimus.30 They showed that anastomotic 
strength (measured by bursting pressure and hydroxyproline content) was reduced 
in both transplanted groups, compared to a non-transplanted group and that this 
decrease was irrespective of immunosuppressant therapy. In 2013 Namkoong et al 
found that the topical use of tacrolimus (0.1%) on full thickness skin wounds in mice 
did not delay or impair the wound healing process.31 The wounds were evaluated by 
computer analysis of dermoscopic images every 2 days. Histological wound scores 
where used at 3, 7 and 11 days after wounding. They used a control group and a 
group that received topical steroid. The rate of wound closure was slowest in the 
steroid-treated group. In the early inflammation phase, tacrolimus slightly diminished 
infiltration of PMNL’s which may lead to an enhanced wound closure in the early 
8
148
Chapter 8
phase. In the same year, we found in our experiment no effect for tacrolimus alone: 
tacrolimus, in three different, clinically relevant dosages, did not interfere with, nor 
did it promote wound strength.32 This result was measured at three different time 
points, in ileum, colon and abdominal wall and in three different dosages of 0.5, 2 
and 5 mg/kg. Our experiment was followed by more experiments of others: in May 
2014 Lin et al discovered that a low dose (0.1 mg/kg) tacrolimus combined with the 
agent AMD3100 was able to enhance wound healing of dorsal skin wounds in mice.33 
In 2014 Cavalheiro Cavalli et all tested bladder healing of rats on tacrolimus.34 
They combined this experiment with ischemia and reperfusion of the left kidney 
and assessed wound healing (which was found to be significantly diminished in 
the tacrolimus treated rats) only by histological findings. Finally, in 2014 Paul et all 
tested a combination of 0.1 mg/kg tacrolimus per day with 20 mg/kg mycophenolate 
mofetil per day in rats that underwent bladder suturing.35 They measured the type 
of collagen using picrosirius red staining, as we did in our experiment, but they also 
quantified the amount of collagen III (the less strong collagen) and collagen I (the 
more aligned and stronger collagen . In the treated group, a predominance of type III 
collagen was seen, in the control group a predominance of type I collagen was seen.
In conclusion: in preclinical research, tacrolimus has been noted to show an 
enhancing effect on wound healing in very low dosages and an impairment of 
wound healing in higher dosages. The experiment we have carried out is the only 
one using multiple dosages and time points and we were not able to show any 
impairment nor enhancement. 
Mycophenolate mofetil
Even fewer preclinical studies have been carried out in the past to determine the 
effect of MMF on wound healing. These studies almost unanimously find a negative 
effect of MMF on wound healing. In 2001 Zeeh at all performed the first preclinical 
studie for wound healing and MMF.36 They treated rats intraperitoneally with 25 mg/
kg MMF three days before surgery. They perfomed a laparotomy, divided the sigmoid 
and performed an anastomose. Two, four and six days after surgery they evaluated 
bursting pressures, histological assessment on hematoxyline and eosin stained 
sections, computed microscopic measurements of colonic crypt depth, protein 
expression of collagen I and fibronectin at the anastomotic site. They also measured 
proliferating cells at the crypts in the bowel tissue using 5-bromo-2’-deoxyuridine 
(BrdU) staining. Bursting pressure and colonic crypt depth were significantly lower 
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than in control rats on day 2 and 4 but not on day 6. Collagen I expression did not 
show a difference between the treated and the control rats. In the treated rats, more 
extended inflammation was noted, significantly so at day six. Less proliferating 
cells were counted at day 2 and day 6 in the MMF administered animals. Another 
experiment, the research of Heinz et all in 2001 was not aimed at dermal or bowel 
wound healing, but interested in the aspect of proliferation.37 They incubated human 
tenon cells that they obtained from tissue explants of two humans undergoing 
cataract surgery, and incubated the cells with MMF. They exposed cells to MMF for 
a long time (up to 20 days) with different concentrations of MMF (from 0.1ųM to 
300 ųM) or exposed cells for 10 minutes with different dosages. Growth inhibition 
proved to be dose dependent and even brief exposure of the cells to higher dosages 
of MMF led to a reversible growth arrest for up to 14 days. In 2005 Sikas et all carried 
out another colon anastomosis experiment with rats.38 Their aim was to check the 
effect of MMF on the expression of Transforming Growth Factor β1 (TGFβ1). The 
rats were administered 40 mg/kg MMF orally. The anastomoses were tested by 
measuring bursting pressure, hydroxyproline content, histological examination and 
immunohistochemical expression of TGFβ1. The medication was started 7 days 
prior to operation. A small segment of colon was resected via laparotomy and the 
bowel was reconstructed with an end/end anastomoses. Assessment was done at 
the third, seventh and fourteenth day. Bursting pressure as well as hydroxyproline 
content were significantly lower in the treated group than in the control group, at 3 
and at 7 days but not at 14 days postoperatively. The control group reached a peak 
of bursting pressure and hydroxyproline at 7 days, the study group continued to 
rise thereafter. On the 7th day, the anastomoses of the study group ruptured at the 
anastomosis line, whereas this occurred only in two animals of the control group. 
On the third day the study population showed a weak inflammatory respons and 
the control group a moderate inflammatory response. On the third and seventh 
day the study population showed weak staining for TGFβ1, and the control group 
showed moderate and strong staining for TGFβ1. On the 14th day both groups 
showed strong staining for TGF β1. They concluded that MMF weakens the integrity 
of the colonic anastomoses particularly during the inflammatory phase of wound 
healing. In 2007 Roos et al, tried to unravel the mechanism of action of MMF by 
performing an experiment in fibroblast cell cultures.39 In fibroblasts incubated 
with MMF in different dosages (0.1-10 ųM) they found a significant dose and time 
dependent reduction of expression of collagen I. Furthermore, they were able to 
assess fibroblast migration in scrape wounding assays and proved that in MMF 
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treated cultures fibroblasts show a lower capacity to migrate. α -Smooth Muscle 
Actin (α-SMA) expression is the hallmark of the myofibroblast phenotype and is 
thought to contribute to their contractile activity and therefore important in wound 
healing. To determine whether MMF had a direct effect on α-SMA expression, the 
α-SMA production was measured in the MMF incubated cultures, showing dose 
dependent reduction in α-SMA production. In 2008 Inglin et all performed a very 
similar experiment as Zeeh in 2001.40 They treated rats with MMF or with MMF 
combined with Insulin Growth Factor in order to determine the protective capacities 
of Insulin Growth Factor. Again they proved that rats, treated by 25 mg/kg MMF 
intraperitoneal daily, showed a lower bursting pressure than control rats at 2 and 
4 days (not on day 6), a lower colonic crypt depth than control rats at day 2 and 4 
and less BrdU stained proliferating cells per crypt at day 2 and 4. In all but the last 
observation Insulin Growth Factor was able to reverse the detrimental effects of 
MMF. Also in 2008 Morath carried out a cell culture experiment like the one Roos 
did in 2001.41 They showed a downregulation of the cytoskeletal proteins vinculin, 
actin and tubulin in fibroblasts exposed to pharmacological doses of MPA which was 
accompanied by a substantial rearrangement of the cytoskeleton in MPA-treated 
fibroblasts. Then they validated the dysfunctional growth by a scratch test, where 
they were able to show an impaired migrational capacity of the fibroblast exposed 
to MPA. They also took biopsies from the surgical incision site obtained at day 0 
and day 7 in MPA-treated transplant recipients and compared these to skin biopsies 
from MPA-untreated patients at day 7 (day 7 control). MPA treatment significantly 
reduced vinculin, actin and tubulin protein expression in skin biopsies. In 2010 
Mahmoud et all carried out an experiment with dogs that they had treated daily 
for 45 days before operation with either prednisone (1 mg/kg), MMF (10 mg/kg), 
sirolimus (1 mg/kg), cyclosporine A (15 mg/kg twice daily) or no drug.42 After this 
period they exposed the dental pulp of the dogs under general anesthesia, followed 
by a capping with Mineral Trioxide Aggregate. The response to capping of the pulp 
is the formation of a dentine barrier, resulting from proliferation tissue. After 65 
days they sacrificed the dogs and examined the tissue for inflammatory response, 
tissue necrosis and hard tissue formation. Results of the sirolimus, cyclosporine A 
and MMF-treated dogs showed significantly more inflammatory repons and tissue 
necrosis. These three groups did not significantly differ from each other. The dogs 
treated with prednisone did not differ from the control dogs. In 2015 Petrova et al 
showed a dose and time dependent effect of MMF on artificial scratch wounds in 
cell cultures, which is similar to the experiment Roos et all carried out in 2001.43 
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In 2016, our group performed an experiment on wound healing of colon and ileum 
anastomoses and abdominal wall in rats with two dosages MMF (20 and 40 mg/
kg).44 Wound strength was measured by bursting pressure and breaking strength 
and histology parameters. Surprisingly, the ileum showed a stronger anastomose 
in the experimental groups. Bursting pressure was higher in the high dose MMF 
group compared to the control group, breaking strength was higher in the low 
dose MMF group compared to the control group. Histology showed poorer bridging 
of the submucosal layer and more polymorfonuclear cell infiltration in the ileum 
specimens of the control group On the other hand we found that MMF in high dose 
had a negative effect on healing of the abdominal wall, which could possibly be 
prevented by delaying the medication for three days.
In conclusion, many authors describe a negative effect of MMF on wound healing, 
tested in many different ways. In rats treated intraperitoneally or treated orally 7 
days before the operation, a decrease in biohistological parameters such as bursting 
pressure or breaking strength in the MMF treated rats were found. Cell culture 
experiments tried to find the reason for this phenomena. We have administered the 
MMF orally from the day of operation, which is more like the clinical human situation 
and find that bursting pressure or breaking strength are not lowered, although 
histology does show an alteration in architecture of the wound and abdominal wall 
tissue shows a decreased strenght of the wound.
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Concern on the effect on wound healing by immunosuppressant agents dates from the 
time these agents were introduced. However, the side effects of medication become 
more relevant with time because the survival of patients with a functioning graft is still 
increasing. 
Patients that received an organ transplant have to be treated with a cocktail of 
immunosuppressant agents, this makes research in patients for a single agent not possible 
and pre-clinical research remains necessary. 
In the first experiment performed in our centre we have measured a strong, dose-
dependent negative effect of everolimus on wound healing, quantified in a bowel 
anastomoses model. The negative effect on wound healing was evident from day 3 to day 
7, but not studied beyond. This led us to the very relevant question: is the negative effect 
on wound healing a transient effect, and should we use a different timing in administering 
of everolimus to our post-transplant patients?
In the second experiment we have followed wound repair for 4 weeks after operation. 
On top of the analysis of anastomoses in ileum and colon, laparotomy wounds in the 
abdominal fascia have also been analyzed, in order to demonstrate that the effect is 
not limited to the intestine but found universally. Another reason to include abdominal 
wall healing is the fact that healing disorders of the abdominal wall are responsible 
for a large body of surgical complications observed in kidney transplantation patients. 
Breaking strength of ileum, colon, and fascia was consistently and significantly reduced in 
the experimental groups at all time points. Anastomotic bursting pressures followed the 
same pattern. Loss of strength was accompanied by a decrease in hydroxyproline content 
after 7 days in all tissue. At 28 days however, the hydroxyproline was significantly higher 
in the fascia and colon healing, despite less strong wound healing, indicating formation 
of a less strong type of collagen. 
In the third experiment, we tried to find out if a short delay in administrating everolimus 
would prevent wound healing problems. Again, mean wound strength after 7 days was 
significantly reduced if everolimus was started on the day of operation, but this could 
be prevented by a delay of 2 days postoperatively for intestinal anastomoses and by 4 
days postoperatively for abdominal wall tissue. In ileum and colon anastomoses strength 
was not affected if drug administration was delayed until the second day. In abdominal 
fascia, values similar to controls were reached if everolimus was withheld until day 4. 
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Summarizing discussion, conclusion and future perspective
The restoration of strength by delaying drug administration appeared to be not always 
accompanied by an increase in hydroxyproline content, especially so in anastomotic tissue. 
Again, this says something about the quantity of collagen but not the quality of collagen.
In the fourth experiment we wanted to test the calcineurine inhibitor tacrolimus which has 
clinically much less wound healing complications. This time we also tested activities of 
matrix metalloproteinase-2 and -9, using collagenase type 1. No biochemical differences 
were seen between the control group and the tacrolimus treated group. Although MMP-9 
activities were low and varied considerably between animals, they appeared higher in the 
tacrolimus groups, especially in ileum. For MMP-2, differences were seen in colon where 
tacrolimus apparently lowered activity at day 3 while increasing it after 7 days. 
In experiment five we have tested (MMF). While biomechanical measurements still 
appeared to give the most dependable outcome we tested in this experiment breaking 
strength, bursting pressure and histology, but did not test hydroxyproline content or MMP 
2 or 9 activity.  Significant differences in wound strength were only seen in ileum tissue 
after 3 days. Surprisingly, the ileum showed a stronger anastomose in the experimental 
groups. Bursting pressure was higher in the high dose MMF group compared to the 
control group, breaking strength was higher in the low dose MMF group compared to 
the control group. Histology showed poorer bridging of the submucosal layer and more 
polymorfonuclear cell infiltration in the ileum specimens of the control group. We did see 
a negative effect of MMF on abdominal wall healing in the high dose group.
With the research carried out up till now we have tried to identify which measurements 
are clinical relevant. We have investigated everolimus, tacrolimus and MMF and found 
everolimus to have a strong negative effect on wound healing. Many groups try to identify 
the mechanism of action of medication on wound healing. This search is hampered by the 
fact that every immunosuppressant drug may have its own mechanism of action and that 
two agents together may have an additive effect. Although many negative and positive 
results have been found, the exact mechanism of action is not unraveled yet. 
Further research should be directed towards more understanding of wound healing in 
different tissues and the effect on wound healing by different agents in the same subject 
at the same time. A classification of wound problems used in the international trials of 
immunosuppressant therapy would be very helpfull. New agents need to be tested for 
wound healing. 
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Abstract English
Immunosuppressant therapy is presently inevitable in solid organ transplantation, 
and most drugs in the poly-drug regimen of medication have been, justly or not, 
associated with wound healing complications. In the fifties and early sixties of the 
previous century immunosuppressant agents were introduced and rapid progression 
in survival of recipients was made. These agents lead to many side effects such as 
malignancies, cardiovascular disease and wound healing disturbances, that were 
all secondary to the goal of preventing rejection in those days. The improvement 
of immunosuppressant therapy and with that the kidney and recipient survival 
brings more awareness to side effects and quality of life. mTOR inhibitors like 
sirolimus and everolimus were introduced in transplantation around the year 2000, 
as an alternative for cyclosporine and steroid maintenance therapy because of the 
relatively strong side effects of these drugs. However, mTOR inhibitors proved to 
have a negative influence on wound healing after transplantation. Tacrolimus is a 
macrolide calcineurin inhibitor. It is superior to cyclosporine in preventing acute 
rejection and improving graft survival which has resulted in an enormous increase 
in use of the agent since introduction in 1989. However, reports on wound healing 
disturbances are contradictory. Mycophenolate mofetil (MMF) has been used as an 
immunosuppressant in kidney, heart and liver transplantation since the nineties. By 
depleting the intracellular concentration of guanosine nucleotides, MMF acts as a 
potent inhibitor of lymphocyte proliferation. Few contradictory reports about the 
relation between wound healing and the use of MMF can be found in the literature.
In chapter 1 we see that although the marked increase in long term survival of 
the patient of earlier decades has now come to a halt, the number of patients 
alive with a functioning kidney transplant is still increasing, especially in Europe. 
Apart from this increase in numbers, patients receiving a kidney transplant are also 
becoming older and more overweight and therefore more at risk for surgery while 
on immunosuppressant therapy. Normal wound healing is explained. This is a very 
complex process in which three specific phases are identified that are referred to 
as the inflammation, proliferation and remodeling phase. The inflammartory phase 
starts with hemostasis followed by attraction of monocyts and neutrophils from the 
capillaries. Monocytes are supported by T and B lymphocytes in the inflammatory 
and in the proliferative phase of wound healing. The inflammatory phase ends 
around four days after the start of the wound and then the proliferative phase 
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starts. Fibroblasts start to produce collagen and epithelialization of the wound is 
initiated at the edges of the wound. The remodeling phase shifts into the remodeling 
phase at approximately 14 days after start of the wound. This phase may take many 
months. In this timeframe the collagen matrix is permanently restructured and the 
mechanical ability of the scar to withstand outside forces is increasing.
In chapter 2 we discuss the clinical research that has been carried out to untangle 
the effect of immunosuppressive agents on wound healing. Wound complications 
are probably the most common surgical complication after transplantation. Many 
clinical studies on immunosuppressant drugs focus on transplant outcome and 
patient survival. Wound healing is usually only part of the standard adverse event 
listing and is not a rigid part of the trial documentation. For the aspect of wound 
healing, the evidence of these clinical trials that are not aimed nor powered to 
measure wound healing is of low quality and contradictory. Apart from that, wound 
healing is not uniformly classified and different descriptions appear in the literature. 
Many prospectives studies report a higher rate of wound complications and 
lymphoceles for kidney transplant recipients on mTOR inhibitors. In the matched-
pair pilot study of Troppman in 2003 we see an apalling 53% of wound healing 
complications. Wound complications were defined as any wound complication that 
needed intervention such as re-laparotomy, seroma aspiration or incisional hernia 
repair. In the last 15 years there have been marked changes in dosing regimens of 
mTOR inhibitors prompted by the wound healing problems in the early years of 
their use. This led to the clinical observation of less wound healing problems. In 
retrospective studies we see that it takes weeks to develop a deep wound infection. 
Different retrospective studies in different decades find an effect of sirolimus on 
wound healing. More recently investigators worried about the concomitant use of 
steroids with sirolimus or the concomitant use of MMF with sirolimus. Most studies 
find a definite effect of sirolumus alone, in combination with MMF. An enourmous 
enhancement of complications in the presence of obesity is noted in many studies. 
The effect tacrolimus is less well defined. 
In chapters 3-7 the experiments we have carried out to entangle the effect of 
different immunosuppressant agents are discussed. In an experimental model of 
wound healing in rats, where wound healing was evaluated by measuring bursting 
pressure and breaking strength of ileum and colon anastomoses and measuring 
biochemical and histological parameters, everolimus caused a massive reduction 
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in anastomotic strength. The reduction was not measured at day 3 postoperatively 
but significantly present at 7 days postoperatively. The data suggested this to 
be caused by an impaired deposition of collagen in the anastomotic area. In a 
sequel experiment the effect was measured up to 28 days postoperative. Breaking 
strength of ileum, colon, and fascia was consistently and significantly reduced in the 
experimental groups at all time points. Anastomotic bursting pressures followed the 
same pattern. Loss of strength was accompanied by a decrease in hydroxyproline 
content after 7 days. The negative effect is therefore not limited to the duration of 
normal wound healing phases. In a third experiment a delay of administration of 
everolimus for 2-4 days after operation was able to prevent a serious loss of wound 
strength, both in the intestine and in the abdominal fascia. In the same experimental 
model of wound healing in rats the agents tacrolimus and mycophenolate mofetil 
were tested. Tacrolimus did not show any negative effect on wound healing despite 
contradictory reports in the literature up till then. MMF did show a small negative 
effect only on abdominal wall in the high dose group.
In chapter 8 we discuss the findings from other pre-clinical research. A diversity of 
tissues has been tested and analysis of repair is mostly restricted to one time point 
only. The most extensive research has been carried out with mTOR inhibitors. In 
2006, we demonstrated for the first time, that the use of mTOR inhibitors results in 
a decrease of wound strength by reducing protein synthesis. Other groups, trying to 
unravel the effect, concluded that wound cells of sirolimus treated rats synthesize 
less nitric oxide and vascular endothelian growth factor (VEGF) and therefore show 
impaired wound healing, and that eosinophil and neutrophil leucocyte infiltration 
were significantly higher in the control rats, and myofibroblast proliferation was 
significantly reduced in the treated rats. In an experiment very much like the 
experiment we carried out, the inflammatory reaction in the anastomosis was 
increased by means of increased myeloperoxidase (MPO)-positive cells and increased 
activity of the matrix-metalloproteinases 2 and 9 (MMP2/9) indicating a delayed 
phase of proliferation. 
Preclinical data on the effects of tacrolimus on wound healing are few and 
contradictory. Wound healing impairment is seen in rats treated with high dosages 
of tacrolimus or treated intraperitoneally. In a very low dose, different investigators 
found a clear promotion of wound healing. We found in our experiment no effect 
for tacrolimus alone: tacrolimus, in three different, clinically relevant dosages, did 
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not interfere with, nor did it promote wound strength. This result was measured at 
three different time points, in ileum, colon and abdominal wall and in three different 
dosages.
Even fewer preclinical studies have been carried out in the past to determine the 
effect of MMF on wound healing. These studies almost unanimously find a negative 
effect of MMF on wound healing, particularly during the inflammatory phase of 
wound healing. In rats treated intraperitoneally or treated orally 7 days before the 
operation, a decrease in bio-histological parameters such as bursting pressure or 
breaking strength in the MMF treated rats were found. Cell culture experiments tried 
to find the reason for this phenomena. We have administered the MMF orally from 
the day of operation, which is more like the clinical human situation and found that 
bursting pressure or breaking strength are not lowered in bowel tissue, although 
histology does show an alteration in architecture of the wound. Abdominal wall 
tissue healing however, does seem to be hampered by a high dose of MMF.
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Abstract Nederlands
Immunosuppressieve medicatie is nog altijd noodzakelijk om afstoting te voorkomen 
bij patiënten die een transplantatie orgaan ontvangen. Door een goede mix van 
immunosuppressieve medicatie kan een goed resultaat, in de vorm van een langdurig 
functionerend orgaan, bereikt worden met zo min mogelijk bijwerkingen. Veel 
chirurgen zijn terecht of onterecht, ongerust over wondgenezingsstoornissen bij 
patiënten die deze medicatie gebruiken. Toen immunosuppressieve medicamenten in 
de jaren 50 en 60 van de vorige eeuw geïntroduceerd werden had dit een zeer positief 
effect op patiënt en orgaan overleving. Bijwerkingen van immunosuppressieve 
middelen zoals het versneld ontstaan van cardiovasculaire ziekte, de ontwikkeling 
van maligniteiten en wondgenezingstoornissen waren ondergeschikt aan het doel 
om de patiënt in leven te houden met een functionerend orgaan. Door geleidelijke 
verbetering en ontwikkeling van nieuwe middelen alsmede door het op elkaar 
afstemmen van deze middelen is de overleving van transplantatie patiënten enorm 
verbeterd. Inmiddels is er mede hierdoor, meer aandacht voor kwaliteit van leven.
mTOR-remmers zoals sirolimus en everolimus werden geïntroduceerd als middelen 
bij transplantatie geneeskunde rond het jaar 2000, als alternatief voor cyclosporine 
en steroiden. In de beginjaren bleken met name mTOR remmers een negatieve 
invloed op wondgenezing na transplantatie te hebben. Veel patiënten ontwikkelden 
seroomholtes in de wond of andere wondproblemen. Tacrolimus is een macrolide 
calcineurine remmer zoals cyclosporine. Tacrolimus is beter in staat om acute 
rejectie te voorkomen dan cyclosporine wat tot een enorme toename van gebruik van 
tacrolimus heeft geleid sinds 1989. Terugmeldingen over wondgenezingstoornissen 
ten gevolge van tacrolimus spreken elkaar tegen. Dit is ook het geval bij het middel 
mycophenolate mofetil. Sinds de jaren negentig wordt mycophenolate mofeltil 
gebruikt in nier, hart en lever transplantatie geneeskunde. Mycophenolate mofetil 
is een sterke remmer van lymfocyt proliferatie en zou een negatief effect op 
wondgenezing kunnen hebben. De weinige vermeldingen in de literatuur hierover 
spreken elkaar tegen.
In hoofdstuk 1 wordt de omvang van het potentiele probleem van 
wondgenezingsstoornissen uitgelegd. We zien dat een geleidelijke maar zekere 
toename in lange termijn overleving van de niertransplantatie patiënt er voor zorgt 
dat het aantal patiënten die leven met een functionerende nier nog steeds toeneemt. 
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Dit is voornamelijk in Europa het geval. Daarnaast worden ontvangers van een nier 
ouder en zwaarlijviger, waarbij vooral het laatste een duidelijke toename van risico 
op wondgenezingsstoornissen oplevert. 
Het verloop van normale wondgenezing wordt behandeld. Dit is een complex proces 
bestaand uit drie specifieke fases: de inflammatie fase, de proliferatie fase en de 
remodellerings fase. De inflammatie fase begint met hemostase, gevolgd door het 
aantrekken van monocyten en neutrofielen uit de capillairen. Monocyten worden 
door T en B lymfocyten ondersteund in deze en de volgende fase. De inflammatoire 
fase eindigt 4 dagen na het ontstaan van de wond met de start van de productie 
van collageen door fibroblasten. Hiermee start de proliferatieve fase waarbij 
epithelialisatie geïnitieerd wordt vanuit de randen van de wond. Na ongeveer 14 
dagen gaat deze fase over in de remodelleringsfase waarbij de collageen matrix die 
ontstaan is continu geherstructureerd wordt en de mechanische weerstand van het 
litteken tegen krachten van buiten beter wordt. Deze fase kan maanden in beslag 
nemen.
In hoofdstuk 2 wordt het klinisch beschikbare bewijs vanuit de trials besproken. 
Wond complicaties zijn de meest voorkomende complicatie na transplantatie 
maar desondanks zijn er weinig studies die wondproblemen als hun voornaamste 
studie object hebben. De meeste studies focussen op patiënt overleving en rejectie 
waardoor wond complicaties meestal een onderdeel zijn van de lange lijst van 
“adverse events” en geen onderdeel van het vaste onderzoeksprotocol. Het bewijs 
voor problemen met wonden ten gevolge van immunosuppressieve medicatie vanuit 
deze trials is daardoor van lage kwaliteit en weinig consistent. Daarnaast bestaat er 
geen goede, uniform gebruikte classificatie van wonden na transplantatie, elke trial 
gebruikt een eigen classificatie. Veel prospectieve medicatie trials in transplantatie 
geneeskunde hebben een hoger aantal lymphoceles gemeld bij het gebruik van 
mTOR-remmers. In de matched-pair pilot studie van Troppman uit 2003,  zien we 
een zeer hoog aantal wondproblemen van 53%, waarbij wondproblemen werden 
gedefinieerd als elke complicatie die een interventie nodig maakt zoals seroom 
aspiratie, hernia chirurgie of opnieuw openen van de wond. Dit heeft geleid tot een 
verandering in het regime en in de dosering van deze middelen. Hiermee werden 
minder wondproblemen gezien. In de loop der tijd werd wel een enorm negatief 
effect gevonden van obesitas op wondgenezing bij transplantatie patiënten. In 
retrospectieve studies zien we dat het weken duurt voordat een diepe wondinfectie 
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klinisch relevant wordt. Verschillende studies uit verschillende tijdperken tonen 
een effect van sirolimus op wondgenezing. Meer recent worden zorgen geuit in de 
literatuur over de combinatie van steroiden en sirolimus of MMF en siroliumus. Het 
effect van tacrolimus is veel minder goed gedefinieerd. 
In hoofdstukken 3-7 worden de experimenten besproken die wij uitgevoerd 
hebben om het effect van verschillende immunosuppressieve medicamenten op 
wondgenezing te ontrafelen. In een dierexperimenteel model in ratten wordt 
wondgenezing geëvalueerd door het meten van “bursting pressure” en “breaking 
strenght” van ileum en colon anastomosen en door het meten van biochemische 
en histologische parameters. In dit model liet everolimus een enorme reductie in 
anastomose sterkte zien. Deze reductie werd niet op dag 3 maar op dag 7 gemeten. 
In een vervolg experiment werd gemeten hoe lang dit effect aanhield en werd 
gezien dat ten minste 28 dagen na operatie de vermindering in anastomose 
sterkte nog meetbaar was. Verlies in sterkte ging samen met een vermindering 
van hydroxyproline hoeveelheid in de anastomose. De data suggereren dat verlies 
in sterkte  veroorzaakt wordt door een verstoorde depositie van collageen in 
de anastomose. In een derde experiment werd gezien dat het uitstellen van de 
medicatie gedurende 2-4 dagen na de operatie voldoende was om het negatieve 
effect van de medicatie teniet te doen.  In het zelfde proefdiermodel werden de 
medicamenten tacrolimus en MMF getest. Tacrolimus liet helemaal geen negatief 
effect zien, MMF liet alleen bij hoge dosis een negatief effect van sterkte van de 
buikwandfascie zien. 
In hoofdstuk 8 worden de bevindingen van ander preklinisch research besproken. Een 
grote diversiteit aan weefsel is onderzocht door verschillende onderzoeksgroepen. 
Meestal zijn de effecten maar op 1 punt na de operatie gemeten. Veel onderzoek is 
verricht naar mTOR-remmers. In 2006, toonden wij voor het eerst aan dat everolimus 
voor een vermindering in wondsterkte kan zorgen door een vermindering in 
proteïne synthese. Andere onderzoeksgroepen in de zoektocht naar de oorzaak 
van dit effect vonden dat cellen in de wonden van ratten die behandeld werden 
met sirolimus minder stikstof oxide  en vasculair endothelial growth factor (VEGF) 
aanmaakten en daardoor verstoorde wondgenezing lieten zien. Daarnaast werd 
gezien dat eosinofiele en neutrofiele infiltratie significant hoger was in ratten 
die niet behandeld waren met mTOR-remmers, en myofibroblast proliferatie 
significant lager in behandelde ratten. In een experiment met dezelfde opzet als 
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het experiment door ons uitgevoerd, werd gezien dat de ontstekingsreactie in de 
anastomose versterkt werd door een toename van myeloperoxidase positieve cellen 
en door verhoogde activiteit van matrix-metalloproteinases (MMP) 2 en 9. Dit wijst 
op een vertraagde fase van proliferatie. Er zijn maar weinig preklinische data over 
de effecten van tacrolimus op wondgenezing. In ratten die werden behandeld met 
een hoge dosis tacrolimus intra peritoneaal werden wondgenezingsstoornissen 
gezien. Een aantal verschillende onderzoeksgroepen vonden juist een promotie van 
wondgenezing bij hele lage doseringen van tacrolimus. In ons experiment vonden 
wij geen enkel effect van tacrolimus alleen: in drie verschillende doseringen, op drie 
verschillende tijdspunten zagen we geen negatief effect op wondgenezing maar 
ook geen promotie van wondgenezing. Het effect van MMF op wondgenezing is 
zeer spaarzaam onderzocht in preklinische setting. De meeste van de uitgevoerde 
studies vinden een negatief effect, vooral tijdens de inflammatoire fase van 
wondgenezing. In ratten die intra peritoneaal of oraal behandeld werden gedurende 
7 dagen voorafgaand aan operatie werd een vermindering van biochemische en 
histologische parameters gezien, evenals een verlaging in “bursting pressure” en 
“breaking strength” van darm anastomosen. In cel cultuur experimenten is gezocht 
naar een reden voor dit fenomeen. Wij hebben MMF oraal toegediend vanaf de eerste 
dag van de operatie, hetgeen de direct postoperatieve periode na transplantatie 
nabootst en zagen alleen een vertraagde wondgenezing in fascie weefsel van de 
buikwand in de hoogst gedoseerde groep, hetgeen ongedaan gemaakt zou kunnen 
worden door uitstel van de medicatie voor korte tijd. In de histologische preparaten 
werd een verstoring in architectuur van de wond gezien.
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Marjan, Rob, Angelique, Jose, Alice, Marlene, Cora, fellow travellers of the Ridhwan 
school; the regular (and in my case, usually irregular) inquiries with you take me 
instantly right to the core. Necessity in this busy life! Thanks for walking with me. 
Aan de basis van alles staan natuurlijk mijn ouders: Mama, je hebt een rotsvast 
vertrouwen in mij. Het maakt je niets uit of ik vaatchirurg ben of een winkeltje zou 
openen, het gaat je niet om status of geld, het gaat je er echt alleen maar om dat 
ik gelukkig ben. Het vertrouwen wat ik van jongs af aan van je kreeg heeft ervoor 
gezorgd dat ik stevig in mijn schoenen sta. Papa; gelukkig geloofde jij in een hemel 
dus ik denk dat je op de dag van mijn promotie met belangstelling mee zal kijken ;) 
Je bent altijd ongelofelijk trots op me geweest. 
Caroline en Frank, zus en broer; jullie wonen allebei nog met je geliefden in Vught 
en ik ben ver weg. Ook als het gaat om familie omstandigheden: ik ben blij dat jullie 
een beetje in de buurt wonen bij mama nu ze ouder wordt. Ik probeer mijn steentje 
bij te dragen vanuit het westen.
Eline, we gaan al lang terug. Helemaal tot de tijd van het Atrium in Heerlen, 
waar ik je leerde kennen via de arts-assistenten vereniging en vervolgens 
fantastische vakanties samen met je beleefde met mijn ambulance bus. 
Elvira; bijna net zo lang geleden kwam jij ineens als nieuwe AIOS chirurgie vooropleiding 
in Heerlen. Tot die tijd was ik de enige vrouw in de grote assistenten groep. Het was zeker 
ook aan jouw enorme collegialiteit te danken dat we zo’n toffe assistenten club hadden. 
Wat fijn dat jullie naast me staan als paranimfen tijdens de verdediging.
Tot slot; Johan, mijn grootste en liefste vriend. Ik ken niemand met een groter hart. 
Je hielp me toen figuren voor een tijdschrift niet aan de vereiste dpi voldeden, maar 
eigenlijk ben je er altijd voor me. Samen is fijn!
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Curriculum Vitae, over de auteur van dit boek:
Ik ben geboren als Martina Cornelia 
Maria Willems op dinsdag 9 januari 
1968 in Vught. Roepnaam: Martine. In 
1988 behaalde ik het VWO diploma aan 
het Maurick College en begon na wat 
omwegen aan de studie Geneeskunde 
aan de Erasmus Universiteit te Rotterdam. 
In 1994 volgde ik gedurende drie maanden 
een keuze co-schap urologie in Mansoura (Egypte) en was daarna bijna voor het 
vakgebied urologie gezwicht, met name vanwege de interesse in de living-related 
niertransplantaties welke in Egypte door de urologen verricht werden. In 1997 werd 
het artsexamen behaald en begon ik als arts-assistent-niet-in-opleiding (anios) 
Intensive Care in het Atrium Medisch Centrum te Heerlen. Na één jaar anios te zijn 
geweest op de Intensive Care en één jaar op de Chirurgie kon ik met de opleiding 
Algemene Heelkunde starten in 1999. Ik werd algemeen chirurg op 1 januari 
2005 en startte als CHIVO vaatchirurgie (chirurg in voortgezette opleiding) in het 
Radboud ziekenhuis te Nijmegen. Hier maakte ik een begin met het onderzoek dat 
ten grondslag ligt aan dit proefschrift. In 2006 werd ik Fellow of the European Board 
of Vascular Surgery door het behalen van het Europees vaatchirurgisch examen.
In 2009 koos ik voor een gecombineerde perifere-academische baan als vaatchirurg 
in het Flevoziekenhuis-AMC, alwaar ik nog steeds met veel plezier werk.
Ik woon samen met Johan Harmeijer op de 108 jaar oude klipperaak Helena, in 
Almere. Samen brengen wij de Helena weer terug in zeilende staat.
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